morbid
mortal
social
disrupt
due
global
acquir
immunodefici
syndrom
aid
pandem
weigh
disproportion
upon
resourcepoor
area
tropic
area
tropic
infecti
diseas
continu
hold
greatest
sway
potenti
interact
human
immunodefici
viru
hiv
infect
tropic
infecti
diseas
great
interact
mark
epidemiolog
complex
aid
pandem
best
describ
sum
discontinu
overlap
epidem
diseas
among
popul
variabl
vari
risk
see
chapter
predomin
mode
transmiss
hiv
perinat
sexual
parenter
result
bimod
distribut
diseas
peak
among
young
children
young
adult
risk
infect
diseas
due
tropic
pathogen
vari
wide
differ
ecolog
polit
socioeconom
condit
includ
access
medic
care
relat
specif
host
factor
age
exposur
pregnanc
behavior
nutrit
host
genet
diseas
due
coinfect
pathogen
may
due
primari
infect
recurr
infect
reactiv
latent
infect
pathogen
risk
factor
respons
acquisit
hiv
may
also
risk
factor
respons
acquisit
coinfect
pathogen
consequ
epidemiolog
complex
preval
express
coinfect
like
variabl
across
ecolog
econom
polit
behavior
cultur
divid
also
cours
consider
biolog
clinic
complex
interact
agent
tropic
diseas
hiv
either
pathogen
potenti
alter
natur
histori
immun
respons
respons
therapi
infect
hiv
abil
influenc
natur
histori
infect
pathogen
facilit
infect
alter
incid
diseas
increas
ratio
diseas
infect
chang
present
diseas
exacerb
cours
diseas
effect
presum
primarili
result
immunosuppress
associ
hiv
infect
abnorm
immun
function
found
essenti
everi
cellular
function
compart
immun
system
aid
although
profound
defect
cellmedi
immun
cmi
appear
greatest
clinic
import
vitro
correl
includ
function
abnorm
cell
progress
failur
prolifer
interleukin
il
product
dysregul
express
molecul
essenti
tcellantigen
present
cell
interact
abnorm
activationinduc
apoptosi
expans
subset
cell
regulatori
cell
potent
inhibitor
immun
respons
self
pathogen
monocytemacrophag
decreas
chemotaxi
intracellular
microbicid
activ
abnorm
cytokin
product
dendrit
cell
reduc
abil
present
antigen
activ
cell
along
effici
transfer
hiv
infect
cell
cell
decreas
cytotox
tlymphocyt
ctl
function
abnorm
activationinduc
apoptosi
natur
killer
nk
cell
decreas
prolifer
product
dysregul
humor
immun
mark
polyclon
bcell
activ
also
seen
function
abnorm
cell
monocytemacrophag
dendrit
cell
function
thought
paramount
suppress
cmi
opportunist
infect
seen
patient
aid
addit
direct
effect
hiv
infect
immun
system
hivseroposit
peopl
may
also
compromis
clinic
signific
way
profound
nutrit
metabol
derang
eg
wast
slim
diseas
therapeut
intervent
eg
corticosteroid
use
treatment
pneumocysti
pneumonia
immun
abnorm
associ
secondari
infect
eg
suppress
cmi
seen
viscer
leishmaniasi
list
infecti
diseas
exacerb
hiv
coinfect
includ
mani
predict
data
demonstr
import
role
cmi
protect
etiolog
agent
sever
pathogen
immun
presum
depend
cmi
appear
exacerb
hiv
coinfect
howev
hiv
experi
natur
caus
reexamin
immunolog
miss
infect
aid
hiv
infect
also
influenc
therapeut
respons
patient
presum
tropic
infect
abil
diagnos
monitor
coinfect
may
compromis
aberr
serolog
respons
includ
fals
posit
due
polyclon
bcell
activ
fals
neg
due
blunt
antigenspecif
antibodi
respons
newli
acquir
pathogen
late
hiv
diseas
fals
serolog
revers
treatment
late
hiv
diseas
diagnosi
may
also
hinder
unusu
present
diseas
coinfect
pathogen
final
plethora
intercurr
patholog
condit
may
lead
dull
ockham
razor
evalu
diseas
aid
patient
singl
pathogen
multipl
pathogen
hiv
infect
side
effect
therapeut
drug
combin
may
respons
present
complaint
given
suboptim
respons
chemotherapi
mani
infect
presenc
profound
immunosuppress
drug
may
need
given
greater
number
longer
durat
mani
pathogen
absenc
immun
reconstitut
result
highli
activ
antiretrovir
therapi
haart
lifelong
suppress
therapi
necessari
drug
therapi
hivinfect
patient
may
complic
increas
rate
drug
allergi
well
untoward
drug
interact
set
polypharmaci
prophylaxi
coinfect
may
compromis
substandard
vaccin
respons
final
presenc
hiv
coinfect
complic
public
health
consequ
tropic
diseas
aid
may
increas
transmiss
secondari
infect
provid
fertil
soil
develop
drug
resist
public
health
resourc
devot
aid
pandem
may
divert
resourc
away
control
prevent
infecti
diseas
presenc
hiv
coinfect
lead
diseas
markedli
greater
incid
sever
standard
definit
opportunist
infect
oi
tropic
infecti
diseas
leishmaniasi
american
trypanosomiasi
chaga
diseas
coinfect
also
demonstr
subtl
effect
cours
diseas
tropic
agent
schistosoma
mansoni
identifi
alter
found
natur
histori
mani
tropic
infect
includ
nematod
organ
latter
group
current
absenc
evid
signific
effect
hiv
express
diseas
respons
treatment
constru
strong
evid
absenc
effect
research
resourc
spent
understand
clinic
epidemiolog
manifest
hiv
pandem
industri
countri
tropic
infecti
diseas
obvious
underrepres
coinfect
hiv
endem
tropic
diseas
mark
low
preval
subtleti
interact
diagnost
difficulti
low
research
prioriti
presenc
signific
interact
like
miss
exampl
despit
research
prioriti
among
tropic
infect
accord
malaria
signific
interact
hiv
infectionth
lack
benefit
increas
pariti
control
malaria
pregnant
womenwa
discov
year
aid
epidem
recogn
less
heavili
studi
pathogen
compar
subtl
interact
like
emerg
time
research
resourc
appropri
direct
focus
oi
may
help
highlight
clearest
data
clinic
express
aid
tropic
agent
known
caus
oi
aid
patient
sever
classic
tropic
pathogen
mostli
found
among
intracellular
protozoan
bacteria
endem
fungi
mark
absenc
metazoan
overal
clinic
express
aid
mani
resourcepoor
area
tropic
appear
involv
differ
spectrum
oi
common
north
america
europ
place
high
incid
pneumocysti
carinii
pneumonia
pcp
dissemin
mycobacterium
avium
cytomegaloviru
cmv
found
resourcerich
north
clinic
express
aid
much
tropic
mark
frequent
tuberculosi
common
seriou
aid
oi
world
chronic
diarrhea
wast
chronic
fever
without
obviou
local
sourc
pulmonari
diseas
contribut
predominantli
tropic
pathogen
latter
common
syndrom
unclear
illumin
problem
much
avail
data
hiv
diseas
tropic
understand
spectrum
aidsassoci
oi
given
area
depend
presenc
adequ
surveil
system
often
lack
resourcepoor
region
tropic
presenc
inadequ
infrastructur
limit
financi
resourc
difficult
access
medic
care
part
social
disadvantag
surveil
like
sporad
involv
mainli
sampl
subgroup
aid
patient
late
stage
diseas
resourc
limit
diagnost
report
like
bias
favor
oi
inexpens
diagnos
misdiagnos
even
common
impress
progress
aid
rapid
subsaharan
africa
industri
countri
rest
data
less
robust
rapid
observ
cours
presum
due
higher
frequenc
virul
coinfect
problem
nutrit
access
medic
care
may
repres
larg
part
systemat
bia
favor
later
initi
diagnosi
hiv
infect
aid
convers
suggest
burden
ill
mortal
earli
hiv
diseas
often
unrecogn
due
highgrad
pathogen
streptococcu
pneumonia
mycobacterium
tuberculosi
salmonella
may
rival
due
oi
latestag
aid
tropic
hiv
shed
light
mani
previous
obscur
human
pathogen
enter
microsporidian
unknown
agent
human
diseas
prior
aid
epidem
other
cryptosporidium
parvum
underappreci
caus
diseas
normal
host
preval
aid
patient
led
systemat
studi
normal
host
list
agent
caus
oi
aid
patient
bound
expand
reason
expect
tropic
region
prime
locat
identif
agent
theoret
experiment
reason
believ
coinfect
significantli
alter
cours
hiv
pathogenesi
central
role
ongo
viral
replic
hiv
pathogenesi
firmli
establish
set
point
concentr
plasma
viremia
correl
well
longterm
clinic
outcom
presum
increas
viral
replic
potenti
acceler
cours
diseas
effici
replic
hiv
cell
depend
cellular
activ
similarli
activ
monocyt
macrophag
dendrit
cell
stimul
hiv
replic
increas
transcript
factor
bind
hiv
long
termin
repeat
region
ltr
enhanc
ltrdirect
transcript
coinfect
pathogen
stimul
immun
cell
activ
either
directli
eg
stimul
signal
pathogen
recognit
receptor
tolllik
receptor
upregul
transcript
factor
transactiv
coinfect
immun
cell
indirectli
eg
promot
gener
proinflammatori
cytokin
tumor
necrosi
activ
cell
part
adapt
immun
respons
immun
activ
also
lead
upregul
express
hiv
coreceptor
therebi
facilit
infect
fresh
cell
immunolog
respons
pathogen
well
purifi
vaccin
antigen
clearli
potenti
enhanc
dynam
burden
hiv
replic
vitro
studi
divers
pathogen
provid
mechanist
support
idea
experiment
evid
also
suggest
immun
activationdriven
augment
hiv
viral
burden
occur
vivo
also
circumstanti
evid
immun
activ
may
enhanc
hiv
pathogenesi
point
remain
somewhat
controversi
howev
whether
immun
activationrel
increas
viral
load
actual
acceler
pathogenesi
hiv
may
depend
whether
chang
transient
immun
treat
acut
infect
chronic
untreat
untreat
infect
reset
set
point
plasma
viremia
particular
coinfect
direct
equat
immun
activ
upregul
hiv
replic
simplist
howev
cell
mechan
activ
appear
critic
whether
viral
replic
induc
suppress
furthermor
activ
proinflammatori
cytokin
product
posit
effect
hiv
replic
goe
hand
hand
activ
antiinflammatori
cytokin
product
inhibit
hiv
replic
gener
proinflammatori
respons
reliabl
induc
counterregulatori
respons
suppress
subsequ
immun
activ
thu
surpris
vitro
studi
provid
mechanist
support
abil
coinfect
pathogen
suppress
hiv
replic
inde
overal
effect
acut
coinfect
pathogen
includ
measl
viru
dengu
viru
orientia
tsutsugamushi
may
decreas
hiv
viral
load
addit
viral
sequela
gener
immunolog
activ
induct
specif
alter
immunoregulatori
environ
host
ubiquit
tropic
pathogen
postul
acceler
cours
hiv
crossregul
subset
cell
distinguish
cytokin
profil
function
activ
cell
produc
among
cytokin
import
classic
macrophag
activ
develop
cmi
gener
humor
respons
involv
complementfix
antibodi
isotyp
cell
produc
among
cytokin
import
altern
macrophag
activ
gener
immunoglobulin
e
ige
respons
eosinophilia
mast
cell
respons
atopi
immunolog
respons
helminth
parasit
domin
product
cytokin
evid
murin
system
show
helminthdriven
polar
shift
immunolog
respons
heterolog
antigen
pathogen
pattern
well
significantli
suppress
viral
clearanc
respons
also
found
impair
antigenspecif
immun
respons
mice
human
helminth
infect
chronic
widespread
tropic
result
prime
immun
system
may
favor
progress
hiv
diseas
sever
mechan
postul
first
immun
system
may
directli
suppress
cellmedi
antihiv
respons
second
hiv
may
preferenti
replic
cell
third
cell
hivseroposit
peopl
undergo
abnorm
activationinduc
apoptosi
thought
play
role
deplet
cell
time
cytokin
amplifi
activationinduc
apoptosi
fourth
cytokin
upregul
hiv
coreceptor
express
cell
monocytemacrophag
note
demonstr
peripher
blood
cell
patient
intestin
helminth
infect
suscept
vitro
infect
hiv
cell
helminthuninfect
patient
although
intrigu
hypothesi
endem
helminth
coinfect
lead
acceler
diseas
cours
hiv
remain
unproven
studi
ethiopia
indic
hiv
viral
load
significantli
higher
individu
variou
helminth
infect
individu
without
helminth
correl
posit
parasit
load
well
decreas
elimin
worm
antiparasit
treatment
howev
similar
studi
perform
uganda
examin
larger
number
patient
convincingli
fail
replic
find
latter
studi
strongli
suggest
helminth
coinfect
associ
faster
progress
hiv
diseas
effect
coinfect
perhap
concret
tropic
diseas
may
lead
directli
increas
risk
infect
hiv
treatment
sever
anemia
induc
malaria
led
hiv
infect
countless
children
transfus
genit
schistosomiasi
like
genit
inflammatori
condit
may
increas
effici
hiv
transmiss
lewi
thoma
wrote
infecti
diseas
usual
result
inconclus
negoti
symbiosi
light
tropic
pathogen
lead
high
infect
diseas
ratio
whether
diseas
present
steril
immun
thought
achiev
infect
intracellular
protozoan
much
case
tropic
subtrop
agent
leishmaniasi
chaga
diseas
ubiquit
agent
toxoplasmosi
thu
lifelong
infect
seriou
diseas
often
result
hivinfect
host
default
side
immunolog
negoti
point
view
clinician
nonendem
area
necessit
obtain
lifetim
travel
histori
hivinfect
patient
perspect
clinician
either
endem
nonendem
area
equal
necessari
appropri
index
suspicion
hiv
coinfect
contempl
possibl
tropic
infecti
diseas
process
give
import
viru
diagnost
due
howev
critic
avoid
let
presenc
suspicion
hiv
infect
distract
care
consider
etiolog
agent
present
respond
similarli
hivseroneg
hivseroposit
peopl
basic
biolog
hiv
progress
diagnosi
treatment
hiv
diseas
epidemiolog
hivaid
tropic
discuss
chapter
chapter
focus
natur
histori
diagnosi
treatment
prevent
tropic
diseas
oi
hiv
patient
distinguish
tropic
pathogen
artifici
side
measl
usual
thought
tropic
diseas
caus
signific
mortal
tropic
today
tuberculosi
pandem
infect
princip
aidsrel
oi
tropic
given
histor
preoccup
field
tropic
medicin
parasit
infect
infect
receiv
close
attent
practic
reason
oi
common
industri
world
discuss
depth
unless
compel
clinic
epidemiolog
reason
multipl
refer
avail
via
internet
discuss
cosmopolitan
oi
detail
inform
specif
organ
discuss
also
found
relev
chapter
book
diagnost
prophylact
therapeut
recommend
discuss
describ
approach
hiv
patient
limit
scarc
medic
resourc
like
mani
strategi
deal
hiv
diseas
evolv
affluent
industri
countri
includ
haart
hightechnolog
diagnost
multidrug
chemoprophylaxi
mani
recommend
may
easili
translat
resourcepoor
area
tropic
malaria
see
chapter
remain
one
import
infecti
diseas
world
today
caus
million
new
case
million
death
year
evid
murin
human
studi
suggest
import
role
cell
protect
immun
bloodstag
malaria
larg
area
share
endemn
preval
medic
signific
interact
hiv
malaria
thu
expect
fear
initi
studi
neg
falciparum
malaria
appear
oi
acceler
progress
hiv
diseas
howev
followup
studi
reveal
signific
bidirect
interact
plasmodium
falciparum
hiv
hiv
replic
peripher
blood
cell
enhanc
exposur
p
falciparum
antigen
vitro
part
induct
increas
hiv
replic
dendrit
cell
also
seen
vivo
infect
plasmodium
chabaudi
mice
transgen
hiv
genom
process
appear
depend
tcell
activ
product
malari
paroxysm
along
antigen
exposur
parasitemia
might
thu
reason
expect
increas
hiv
viral
load
inde
clinic
studi
malawi
shown
p
falciparum
infect
associ
increas
hiv
viral
burden
peripher
well
placent
blood
treatment
associ
reduct
viral
load
although
remain
elev
compar
control
durat
studi
whether
malariamedi
increas
hiv
replic
acceler
cours
hiv
diseas
remain
determin
first
signific
clinic
effect
hiv
malaria
found
set
pregnanc
area
high
malari
endemn
high
degre
immun
women
childbear
age
develop
sever
malaria
compromis
pregnanc
placent
vasculatur
shield
parasit
erythrocyt
system
immun
respons
allow
local
erythrocyt
replic
parasit
placent
parasitemia
associ
low
birth
weight
henc
increas
infant
mortal
local
uteroplacent
immun
respons
restrict
parasit
replic
howev
effect
local
respons
increas
subsequ
pregnanc
pressur
recurr
malari
exposur
studi
perform
rural
malawi
demonstr
benefici
effect
matern
placent
neonat
pariti
control
parasitemia
pregnanc
markedli
attenu
face
hiv
coinfect
sinc
multipl
studi
perform
subsaharan
africa
probe
effect
coinfect
outcom
pregnanc
studi
shown
hiv
infect
associ
increas
rate
level
peripher
placent
parasitemia
clinic
malaria
matern
anemia
pregnant
women
coinfect
associ
higher
risk
low
birth
weight
preterm
birth
intrauterin
growth
retard
postnat
infant
mortal
although
placent
parasitemia
associ
increas
placent
hiv
viral
load
coinfect
patient
remain
unclear
whether
malaria
infect
increas
risk
mothertochild
transmiss
hiv
conflict
result
enhanc
protect
effect
publish
world
health
organ
technic
consult
recommend
hivinfect
pregnant
women
risk
malaria
alway
protect
insecticidetr
bed
net
along
accord
hiv
stage
either
intermitt
prevent
treatment
sulfadoxinepyrimethamin
daili
trimethoprimsulfamethoxazol
cotrimoxazol
tmpsmx
prophylaxi
hiv
infect
associ
increas
incid
parasitemia
risk
clinic
malaria
significantli
higher
hivinfect
adult
risk
increas
decreas
cell
count
notabl
hiv
infect
also
found
risk
factor
sever
malaria
nonimmun
popul
area
unstabl
transmiss
final
although
earli
studi
found
evid
treatment
prophylaxi
malaria
alter
hiv
coinfect
risk
malaria
treatment
failur
recent
found
higher
hiv
posit
individu
hiv
proteas
inhibitor
current
use
haart
understudi
interact
varieti
drug
use
malaria
prophylaxi
treatment
varieti
proteas
inhibitor
well
nonnucleosid
revers
transcriptas
inhibitor
delaviradin
efavirenz
inhibit
hepat
cytochrom
enzym
princip
effect
isoform
ritonavir
potent
inhibitor
although
isoform
may
also
affect
nevirapin
efavirenz
caus
secondari
induct
effect
ritonavir
nelfinavir
well
antimalari
agent
larg
metabol
via
enzym
mefloquin
appear
except
although
detail
remain
poorli
understood
proguanil
chloroquin
metabol
appear
larg
isoform
respect
chloroquin
also
undergo
appreci
renal
excret
wherea
doxycyclin
larg
avoid
pathway
vivo
detail
understand
atovaquon
metabol
appear
lack
actual
publish
pharmacokinet
data
suggest
signific
drugdrug
interact
nelfinavir
indinavir
mefloquin
ritonavir
minim
effect
mefloquin
pharmacokinet
wherea
mefloquin
suppress
ritonavir
plasma
level
atovaquon
increas
serum
zidovudin
azt
level
approxim
although
azt
effect
pharmacokinet
atovaquon
summari
actual
pharmacokinet
easili
predict
theoret
consider
pauciti
data
base
current
data
mefloquin
doxycyclin
chloroquin
malaron
atovaquon
proguanil
like
safe
retain
efficaci
prophylaxi
sensit
strain
malaria
among
malaria
treatment
option
quinidin
quinin
predominantli
metabol
isoform
larg
threefold
increas
area
curv
auc
quinidin
expect
ritonavir
result
quinidin
consid
contraind
ritonavir
like
appli
quinin
well
actual
data
howev
whether
clinic
relev
effect
proteas
inhibitor
metabol
artemisinin
compound
depend
least
part
remain
unknown
uncompl
malaria
probabl
safe
treat
chloroquin
sensit
pyrimethaminesulfadoxin
mefloquin
use
quinin
quinidin
artemisinin
compound
remain
essenti
parenter
therapi
sever
chloroquineresist
malaria
ritonavir
andor
proteas
inhibitor
delaviridin
efavirenz
normal
load
dose
quinin
quinidin
probabl
given
along
reduct
mainten
infus
dose
obvious
care
monitor
need
done
potenti
fatal
arrhythm
consequ
quininequinidin
overdosag
set
given
lack
data
howev
underdos
may
also
potenti
problem
washout
period
metabol
effect
ritonavir
thought
hour
higher
incid
allerg
respons
sulfonamid
make
pyrimethaminesulfadoxin
fansidar
less
attract
malaria
therapi
hivseroposit
patient
least
north
american
popul
furthermor
stevensjohnson
syndrom
relat
advers
mucocutan
reaction
longact
sulfa
compound
sulfadoxin
contraind
benefit
use
malaria
prophylaxi
develop
countri
presenc
hiv
infect
alter
predict
valu
fever
empir
diagnosi
malaria
area
high
preval
hiv
malaria
common
practic
empir
treat
febril
adult
malaria
lead
gross
overestim
overtreat
malaria
final
treatment
sever
anemia
due
malaria
one
common
reason
blood
transfus
subsaharan
africa
malaria
thu
provid
indirect
import
risk
factor
acquisit
hiv
infect
children
blood
suppli
well
screen
genu
babesia
contain
known
speci
tickborn
intraerythrocyt
protozoan
parasit
wild
domest
vertebr
predominantli
tropic
subtrop
area
human
babesi
diseas
report
mostli
temper
climat
see
chapter
signific
clinic
interact
hiv
infect
suggest
babesia
microti
rais
possibl
diseas
tropic
babesi
speci
may
risk
aid
patient
provid
rational
current
discuss
five
report
case
babesiosi
due
b
microti
hivinfect
peopl
two
case
occur
splenectom
patient
one
chronic
lowlevel
hemolysi
due
babesia
prior
splenectomi
like
patient
intact
spleen
present
fever
unknown
origin
fuo
face
count
less
one
fuo
last
month
associ
night
sweat
dri
cough
weight
loss
dyspnea
exert
persist
parasitemia
clinic
success
chemotherapi
led
need
chronic
suppress
therapi
anoth
patient
recurr
diseas
led
retreat
month
initi
therapi
quinin
plu
clindamycin
atovaquon
plu
azithromycin
therapeut
efficaci
acut
diseas
hivinfect
patient
chronic
suppress
therapi
appear
indic
vectorborn
diseas
vector
avoid
effici
way
prevent
diseas
signific
interact
hiv
infect
remain
describ
european
bovin
babesia
speci
babesia
bovi
babesia
divergen
emerg
agent
human
babesiosi
wa
ca
mo
north
america
except
toxoplasma
gondii
leishmania
common
tissu
protozoan
caus
oi
patient
aid
see
chapter
surpris
cellular
immun
respons
particular
immun
respons
critic
protect
leishmania
compet
axi
cellular
respons
becom
increasingli
compromis
progress
hivrel
immunosuppress
provid
favor
environ
diseas
due
leishmania
speci
furthermor
vitro
evid
suggest
coinfect
macrophag
hiv
leishmania
directli
upregul
parasit
replic
vivo
overal
loss
immunolog
control
parasit
infect
reflect
often
aberr
manifest
viscer
leishmaniasi
vl
aid
includ
peripher
parasitemia
found
coinfect
peopl
parasit
dissemin
unusu
bodi
compart
aidsrel
oi
occur
low
tcell
count
leishmaniasi
may
due
either
primari
leishmania
infect
reactiv
clinic
latent
infect
although
publish
data
interact
hiv
leishmania
focu
larg
effect
hiv
leishmani
infect
diseas
note
also
vitro
vivo
evid
leishmania
augment
hiv
replic
although
leishmaniasi
worldwid
distribut
tropic
subtrop
normal
requir
arthropod
vector
sandfli
move
organ
sylvat
zoonot
cycl
human
host
certain
speci
leishmania
leishmania
tropica
leishmania
donovani
locat
eg
syria
india
respect
anthroponot
humantohuman
cycl
via
sandfli
exist
situat
intraven
drug
use
practic
transmiss
simplifi
even
direct
persontoperson
transfer
via
contamin
needl
syring
gener
howev
leishmaniasi
rural
periurban
zoonosi
experi
vl
complic
hivaid
mediterranean
countri
indic
mani
perhap
leishmani
infect
acquir
hiv
hiv
infect
alreadi
occur
transmiss
agent
occur
share
needl
syring
intraven
drug
user
could
theoret
reduc
aggress
program
educ
provis
clean
needl
syring
effect
program
sandfli
vector
control
interrupt
transmiss
heavili
infect
human
reservoir
human
well
usual
cycl
infect
dog
human
vector
control
also
way
prevent
coinfect
leishmania
acquir
hiv
sexual
rel
high
preval
latent
leishmani
infect
would
appear
reactiv
latent
infect
could
account
increas
number
hivleishmania
coinfect
howev
concept
alway
support
epidemiolog
evid
greater
variabl
zymodem
enzym
marker
found
parasit
isol
hivinfect
uninfect
patient
one
seri
five
isol
recov
hivinfect
patient
previous
encount
immunocompet
peopl
either
vl
cutan
leishmaniasi
cl
find
certain
strain
leishmania
typic
caus
cutan
diseas
recov
bone
marrow
coinfect
patient
could
support
either
primari
reactiv
hypothesi
normal
age
distribut
vl
caus
l
donovani
includ
adult
well
children
contrast
vl
due
leishmania
infantum
affect
children
predominantli
often
age
year
younger
spain
intraven
drug
use
account
major
hivleishmania
coinfect
age
distribut
vl
revers
case
occur
young
adult
male
fact
coinfect
patient
demonstr
organ
peripher
blood
smear
fact
sandfli
readili
infect
feed
coinfect
patient
provid
evid
addit
anthroponot
cycl
transmiss
set
summari
although
reactiv
latent
leishmani
infect
difficult
exclud
increas
evidencein
southern
europ
leastfavor
primari
infect
certain
strain
leishmania
main
mechan
coinfect
hivaid
spread
hiv
pandem
increas
epidemiolog
overlap
area
hiv
leishmania
occur
particularli
eastern
africa
india
brazil
europ
case
report
approxim
countri
although
bulk
case
report
southern
europ
note
rel
case
american
mucocutan
leishmaniasi
recogn
hivinfect
subject
propens
dissemin
diseas
presenc
hiv
appear
limit
certain
speci
leishmania
bulk
inform
vl
complic
hiv
infect
involv
l
infantum
mediterranean
region
presum
abil
viscer
influenc
hiv
also
appli
l
donovani
southern
asia
africa
l
chagasi
latin
america
howev
document
still
somewhat
meager
one
possibl
reason
poor
overlap
geograph
distribut
leishmaniasi
caus
speci
distribut
well
preval
hiv
infect
speci
leishmania
caus
cl
implic
rare
oi
hivaid
one
instanc
l
braziliensi
recov
bone
marrow
patient
tcell
count
less
main
clinic
pictur
case
well
other
includ
patient
infect
leishmania
major
one
multipl
cutan
lesion
resembl
diffus
cl
febril
ill
longer
week
durat
hivinfect
person
lifetim
histori
travel
leishmaniaendem
region
world
certainli
rais
suspicion
leishmaniasi
complic
hiv
infect
patient
intraven
drug
user
travel
southern
europ
especi
spain
franc
itali
would
particularli
pertin
clinic
diagnosi
vl
leishmaniahiv
coinfect
peopl
may
difficult
hivinfect
patient
oppos
nonhivinfect
patient
exhibit
characterist
clinic
pattern
name
fever
splenomegali
hepatomegali
increas
immunosuppress
clinic
evid
ectop
local
parasit
becom
common
gastrointestin
laryng
pulmonari
periton
involv
report
singl
multipl
cutan
form
andor
mucos
mucocutan
lesion
also
describ
aid
patient
worldwid
immunocompet
peopl
test
antileishmani
antibodi
use
diagnosi
vl
b
cell
activ
promin
larg
amount
specif
nonspecif
antibodi
produc
contrast
approxim
coinfect
patient
lack
detect
antibodi
level
situat
may
differ
instanc
leishmani
infect
preced
hiv
infect
impair
immun
respons
ensu
gradoni
associ
suggest
type
serolog
data
could
use
indic
sequenc
acquisit
two
infect
support
concept
provid
report
ethiopia
seven
case
vl
hiv
coinfect
highli
elev
antileishmani
antibodi
titer
patient
live
mani
year
leishmaniasisendem
area
ethiopia
recombin
antigen
appear
highli
sensit
specif
immunodiagnosi
vl
due
l
donovani
l
chagasi
patient
without
complic
hiv
infect
howev
sensit
immunodiagnosi
cutan
case
turkey
greatli
reduc
compar
case
vl
util
diagnost
clear
hivseroposit
peopl
peripher
parasitemia
display
mani
hiv
coinfect
individu
allow
detect
parasit
blood
approxim
case
cultur
polymeras
chain
reaction
pcr
buffycoat
prepar
posit
respect
abund
evid
success
treatment
leishmani
diseas
regardless
drug
use
ultim
requir
intact
cmi
coinfect
patient
victim
doubl
insult
immun
system
vl
associ
antigenspecif
tcell
unrespons
dysfunct
cytokin
respons
situat
compound
immunolog
abnorm
associ
hiv
infect
therapi
vl
face
hiv
coinfect
remain
controversi
larg
due
lack
firm
data
drug
use
treatment
vl
normal
host
includ
pentaval
antimoni
amphotericin
b
prepar
util
treatment
hiv
coinfect
patient
albeit
significantli
less
efficaci
amphotericin
b
convent
drug
form
leishmaniasi
includ
viscer
diseas
liposom
encapsul
amphotericin
theoret
advantag
target
monocytemacrophag
host
cell
leishmani
parasit
coinfect
patient
initi
parasitolog
cure
treatment
pentaval
antimoni
amphotericin
b
deoxychol
amphotericin
b
lipid
complex
among
option
treatment
lipid
formul
amphotericin
b
appear
similar
efficaci
less
sever
toxic
drug
howev
experi
lipid
formul
amphotericin
b
coinfect
patient
remain
meager
lipid
formul
also
quit
expens
trial
aim
optim
therapi
vl
aid
clearli
need
even
initi
cure
relaps
predict
time
occur
coinfect
individu
within
year
optim
drug
secondari
prophylaxi
remain
unclear
pentamidin
given
everi
week
liposomeencapsul
amphotericin
everi
week
week
use
secondari
prophylaxi
miltefosin
oral
agent
safe
effect
treatment
indian
patient
vl
shown
promis
earli
compassionateus
treatment
vl
hivinfect
subject
optim
treatment
suppress
regimen
miltefosin
hiv
patient
may
establish
role
new
antileishmani
agent
therapi
suppress
prophylaxi
vl
hivinfect
patient
fact
signific
reduct
incid
aidsrel
vl
seen
southern
europ
advent
haart
along
fact
haartrel
immun
reconstitut
allow
discontinu
secondari
prophylaxi
oi
rais
hope
haart
allow
safe
discontinu
secondari
prophylaxi
vl
detail
level
immunolog
virolog
respons
need
termin
secondari
prophylaxi
remain
determin
american
trypanosomiasi
chaga
diseas
american
trypanosomiasi
chaga
diseas
see
chapter
wellrecogn
oi
aid
caus
organ
trypanosoma
cruzi
bloodsuck
vector
triatomin
bug
transmit
protozoan
restrict
western
hemispher
wide
distribut
unit
state
chile
argentina
hivrel
chaga
diseas
report
date
larg
repres
reactiv
chronic
infect
cours
hivinduc
immunosuppress
primari
infect
face
aid
surpris
given
differ
pattern
epidemiolog
risk
infect
larg
rural
cruzi
larg
urban
hiv
oi
expect
appear
outsid
geograph
bound
note
activ
latent
cruzi
infect
well
exacerb
primari
infect
transmit
blood
transfus
also
well
describ
face
iatrogen
immunosuppress
use
solid
organ
transplant
therapi
hematolog
malign
avail
data
suggest
clinic
cruzi
reactiv
face
hiv
coinfect
occur
larg
tcell
count
less
clinic
reactiv
commonli
involv
central
nervou
system
trypanosoma
cruzi
probabl
late
recogn
opportunist
pathogen
hiv
infect
promin
featur
central
nervou
system
diseas
similar
toxoplasm
meningoenceph
enlarg
hemorrhag
foci
produc
mass
effect
simul
brain
tumor
lesion
often
multipl
comput
tomograph
ct
scan
magnet
reson
imag
mri
show
ring
enhanc
preferenti
involv
white
matter
toxoplasm
enceph
may
also
present
patient
cerebrospin
fluid
csf
find
includ
slight
pleocytosi
increas
protein
slightli
decreas
glucos
patient
presenc
trypanosom
histolog
brain
lesion
show
necrot
foci
hemorrhag
infiltr
inflammatori
cell
amastigot
form
parasit
abund
glial
cell
macrophag
occasion
neuron
cell
myocard
common
autopsi
find
die
aidsrel
cruzi
meningoenceph
myocard
often
clinic
silent
clinic
manifest
present
involv
arrhythmia
congest
heart
failur
correct
diagnosi
reactiv
cruzi
infect
depend
first
consid
possibl
base
geograph
origin
patient
appreci
clinic
pictur
neurolog
sign
present
perform
ct
scan
mri
key
imag
pattern
central
nervou
system
cn
cruzi
infect
indistinguish
toxoplasm
enceph
direct
microscop
examin
centrifug
sediment
csf
often
show
motil
trypanosom
fever
system
sign
present
direct
examin
buffi
coat
microhematocrit
tube
may
also
show
motil
trypanosom
sinc
serum
antibodi
cruzi
indic
previou
infect
parasit
test
use
rule
reactiv
infect
neg
test
inconclus
biopsi
brain
lesion
demonstr
characterist
organ
done
pcr
blood
csf
requir
research
laboratori
facil
clinic
differenti
hivrel
reactiv
chaga
diseas
reactiv
chronic
chagas
diseas
may
difficult
hivrel
reactiv
associ
high
parasitemia
howev
wherea
parasitemia
chronic
diseas
low
inde
even
absenc
overt
clinic
reactiv
chronic
chaga
diseas
associ
higher
percentag
level
parasitemia
coinfect
hiv
independ
count
hiv
seroneg
effect
coinfect
appear
bidirect
hiv
viral
load
care
document
increas
simultan
asymptomat
increas
cruzi
parasitemia
subsequ
return
baselin
face
success
antiparasit
treatment
nifurtimox
benznidazol
moder
antitrypanosom
activ
standard
drug
recommend
treatment
chaga
diseas
simpli
enough
experi
evalu
effect
drug
treatment
cruzi
infect
complic
hiv
aid
especi
case
meningoenceph
inform
avail
penetr
drug
cn
surviv
time
report
case
coinfect
short
patient
report
nishioka
cowork
surviv
day
disappear
trypanosom
blood
csf
well
clearanc
brain
lesion
treat
benznidazol
dose
mgkgday
day
clinic
improv
reduct
size
brain
lesion
attribut
treatment
benznidazol
plu
later
itraconazol
fluconazol
anoth
patient
coinfect
surviv
least
month
although
report
experi
use
itraconazol
fluconazol
treatment
american
trypanosomiasi
human
itraconazol
report
effect
experiment
infect
infect
mice
given
littl
mgkgday
protect
death
concentr
itraconazol
low
inhibit
replic
parasit
macrophag
recommend
treatment
cruzi
infect
hivposit
individu
start
earli
reactiv
process
parasitemia
detect
irrevers
endorgan
damag
occur
strategi
would
hing
serolog
identif
risk
someth
indic
hivinfect
individu
appreci
risk
cruzi
infect
although
data
lack
note
immunolog
reconstitut
haart
therapi
like
provid
consider
prophylact
therapeut
benefit
diseas
signific
interact
agent
african
trypanosomiasi
see
chapter
hiv
delin
although
cell
macrophag
respons
thought
import
protect
host
respons
trypanosomiasi
trypanosomiasi
suppress
cellular
immun
respons
biolog
interact
two
plausibl
signific
epidemiolog
associ
trypansoma
brucei
gambiens
hiv
found
whether
hiv
alter
clinic
cours
either
west
east
african
trypanosomiasi
unclear
anecdot
evid
hiv
may
complic
therapi
west
african
trypanosomiasi
howev
patient
treat
melarsoprol
rural
hospit
congo
hivneg
patient
recov
wherea
hivposit
patient
die
treatment
like
due
treatmentrel
encephalopathi
fourth
fail
respond
therapi
trypanosomatid
addit
two
genera
leishmania
trypanosoma
known
caus
diseas
human
trypanosomatida
famili
includ
genera
protozoa
parasit
vertebr
insect
plant
three
report
hivinfect
individu
present
symptom
typic
viscer
leishmaniasi
ultrastructur
isoenzym
andor
kinetoplast
dna
analys
isol
lesion
parasit
indic
respons
organ
actual
belong
one
latter
genera
strong
implic
hivrel
immunosuppress
render
human
vulner
normal
nonpathogen
lower
trypanosomatid
toxoplasma
gondii
ubiquit
parasit
mammal
throughout
world
see
chapter
latent
infect
last
lifetim
host
mainten
latenc
depend
cmi
respons
reactiv
latent
infect
common
increas
immunosuppress
aid
princip
manifest
reactiv
toxoplasm
enceph
te
thu
common
oi
aid
patient
throughout
world
incid
te
proport
preval
latent
infect
popul
risk
aid
unit
state
rate
latent
infect
vari
pari
rate
acquisit
toxoplasma
infect
age
depend
wide
variat
infect
rate
even
narrow
geograph
area
preval
rate
tropic
vari
measur
commun
fall
broad
middl
rang
unit
state
prior
advent
haart
onethird
toxoplasmaseroposit
aid
patient
develop
te
absenc
prophylaxi
case
patient
less
less
preval
te
aid
patient
tropic
unclear
burden
thought
immens
underdiagnos
autopsi
seri
includ
examin
brain
suggest
diseas
preval
rate
latestag
aid
patient
abidjan
divoir
mexico
citi
kampala
uganda
presumpt
diagnosi
te
base
clinic
present
posit
toxoplasma
serolog
characterist
neuroradiolog
featur
final
clinic
diagnosi
made
base
clinic
radiograph
respons
specif
chemotherapi
less
common
manifest
toxoplasmosi
aid
includ
pneumonia
retinochoroid
myocard
orchiti
gastrointestin
involv
reader
refer
one
mani
excel
review
toxoplasma
aid
inform
clinic
manag
cosmopolitan
oi
five
percent
te
occur
reactiv
acut
infect
prevent
transmiss
gondii
toxoplasmaseroneg
hivinfect
peopl
two
facet
avoid
ingest
tissu
cyst
intermedi
mammalian
host
ie
cook
meat
well
avoid
oocyst
definit
host
cat
avoid
cat
fece
around
dwell
probabl
suffici
oocyst
viabl
month
moist
soil
contamin
fresh
veget
may
common
method
human
infect
foodstuff
probabl
wash
well
cook
primari
prophylaxi
tmpsmx
prefer
taken
toxoplasmaseroposit
hiv
patient
tcell
count
less
safe
discontinu
primari
secondari
prophylaxi
haartrel
immun
reconstitut
sustain
tcell
count
freeliv
ameba
freeliv
ameba
acanthamoeba
balamuthia
genera
see
chapter
rare
caus
opportunist
enceph
cutan
diseas
latestag
aid
case
report
unit
state
worldwid
environment
distribut
ubiquit
protozoan
fact
diagnosi
often
postmortem
suggest
underdiagnosi
widespread
tropic
elsewher
granulomat
ameb
enceph
gae
subacut
chronic
diseas
compromis
host
caus
multipl
speci
acanthamoeba
well
balamuthi
mandrillari
gener
caus
death
week
month
clinic
patholog
data
well
anim
model
suggest
pathogenesi
gae
involv
hematogen
dissemin
brain
initi
upper
lower
respiratori
perhap
cutan
site
infect
patholog
chang
form
necrot
granulomat
inflamm
found
predominantli
posterior
neuraxi
acanthamoeba
balamuthia
isol
soil
water
includ
tap
water
bottl
water
chlorin
pool
natur
sourc
freshand
seawat
air
throughout
world
isol
acanthamoeba
nasopharynx
healthi
adult
indic
organ
may
common
constitu
normal
flora
cellular
immun
along
antibodi
complement
appear
critic
protect
immun
acanthamoeba
invas
diseas
occur
immunocompromis
debilit
occasion
enceph
balamuthia
mandrillari
occur
appar
normal
host
case
gae
report
aid
patient
implic
acanthamoeba
organ
includ
acanthamoeba
castellani
acanthamoeba
culbertsoni
acanthamoeba
polyphaga
acanthamoeba
rhysod
acanthamoeba
divionensi
dissemin
cutan
diseas
subacut
granulomat
dermat
sgd
featur
mani
case
preced
clinic
cerebr
involv
week
month
sgd
sole
manifest
invas
diseas
patient
report
tcell
count
less
median
time
present
count
report
histori
reveal
clinic
evid
latestag
aid
gae
aid
patient
mark
rapid
cours
death
day
pauciti
wellform
granuloma
comparison
host
diseas
symptomat
involv
nasopharynx
paranas
sinus
skin
prior
develop
gae
common
aid
patient
cutan
lesion
usual
nodular
subsequ
enlarg
ulcer
metastat
spread
lesion
quit
pleomorph
pustul
plaqu
eschar
cellul
howev
confus
catscratch
diseas
cryptococcosi
sporotrichosi
bacillari
angiomatosi
mycobacteri
infect
vascul
common
present
cerebr
diseas
fever
headach
focal
neurolog
deficit
profound
chang
mental
statu
also
frequent
neuroradiolog
find
mimic
toxoplasm
enceph
multipl
enhanc
mass
lesion
surround
edema
csf
find
quit
variabl
high
index
suspicion
tissu
microbiolog
diagnosi
key
antemortem
identif
dissemin
acanthamoeba
infect
wet
mount
csf
occasion
use
trophozoit
cyst
found
tissu
biopsi
cyst
mistaken
sporangia
rhinosporium
prototheca
cryptococci
trophozoit
mistaken
tissu
macrophag
acanthamoeba
isol
cultur
escherichia
coliseed
nonnutri
agar
tissu
cultur
medium
identif
speci
even
differenti
acanthamoeba
balamuthia
possibl
morpholog
immunofluoresc
techniqu
differenti
acanthamoeba
group
level
tissu
section
cultur
organ
treatment
dissemin
diseas
due
organ
difficult
chemotherapeut
regimen
clearli
efficaci
agent
possibl
clinic
util
combin
therapi
includ
pentamidin
sulfamethazin
sulfadiazin
fluconazol
itraconazol
ketoconazol
macrolid
phenothiazin
rifampin
may
valu
test
clinic
isol
drug
sensit
isol
cerebr
lesion
may
role
surgic
excis
possibl
foreshadow
newli
emerg
oi
case
primari
ameb
meningoenceph
due
appar
newli
recogn
ameba
associ
thermal
pollut
water
report
patient
latestag
aid
spain
enter
coccidiosi
isospora
cryptosporidium
cyclospora
trio
coccidian
protozoaisospora
belli
cryptosporidium
spp
cyclospora
eimeria
cayetanensisar
promin
caus
selflimit
small
bowel
diarrhea
immunolog
normal
host
well
caus
chronic
sever
diseas
face
hiv
coinfect
cosmopolitan
infect
infect
fourth
organ
sarcocysti
homini
respons
enter
dissemin
coccidioisi
human
appear
report
hivinfect
individu
cryptosporidium
spp
see
chapter
addit
common
human
pathogen
cryptosporidium
homini
previous
cryptosporidium
parvum
human
genotyp
genotyp
varieti
zoonot
speci
also
infect
human
includ
cryptosporidium
parvum
previous
bovin
genotyp
genotyp
cryptosporidium
cani
cryptosporidium
feli
cryptosporidium
meleagridi
cryptosporidium
muri
zoonot
speci
may
caus
sever
human
diseas
may
occur
commonli
immunocompromis
peopl
high
preval
diseas
lack
effect
specif
treatment
cryptosporidiosi
particularli
common
sever
problem
oi
throughout
world
chronic
infect
diseas
frequent
cell
count
less
associ
increas
mortal
use
haart
therapi
led
decreas
preval
cryptosporidi
diseas
hivinfect
individu
four
clinic
syndrom
cryptosporidi
diarrheal
diseas
patient
aid
limn
chronic
diarrhea
choleralik
diseas
transient
diarrhea
relaps
ill
sever
end
spectrum
seen
larg
tcell
count
less
less
commonli
extraintestin
site
secondarili
involv
includ
biliari
tract
stomach
pancrea
lung
paranas
sinus
middl
ear
biliari
tract
involv
present
right
upper
quadrant
pain
nausea
vomit
fever
repres
common
clinic
import
site
found
onefourth
patient
aidsrel
intestin
diseas
prior
use
haart
individu
tcell
count
less
particular
risk
develop
symptomat
biliari
diseas
antimicrobi
agent
demonstr
consist
efficaci
hivrel
cryptosporidiosi
immun
reconstitut
haart
pursu
haart
fail
avail
varieti
antimicrobi
agent
includ
nitazoxanid
azithromycin
paromomycin
atovaquon
may
tri
support
treatment
fluid
nutrit
antimotil
agent
play
obviou
therapeut
role
isospora
belli
see
chapter
diseas
due
isospora
less
cosmopolitan
due
cryptosporidia
common
tropic
subtrop
area
isosporiasi
usual
present
chronic
wateri
diarrhea
weight
loss
without
vomit
abdomin
pain
fever
invas
gallbladd
tissu
similar
describ
cryptosporidium
describ
along
dissemin
involv
mesenter
tracheobronchi
lymph
node
set
hiv
coinfect
promin
tissu
eosinophilia
involv
lamina
propria
often
present
diagnost
therapeut
issu
cover
chapter
tmpsmx
provid
effect
therapi
pyrimethamin
leucovorin
provid
second
option
clinic
respons
usual
rapid
relaps
common
absenc
immun
reconstitut
suppress
therapi
indic
cyclospora
eimeria
cayetanensi
see
chapter
clinic
pictur
enter
infect
c
cayetanensi
aid
appear
similar
due
coccidia
interest
biliari
tract
involvementa
evidenc
right
upper
quadrant
pain
elev
alkalin
phosphatas
thicken
gallbladd
ultrasoundha
also
describ
cyclospora
infect
thu
three
enter
coccidia
human
capabl
invad
gallbladd
diagnost
therapeut
issu
cover
chapter
isosporiasi
cyclosporiasi
aid
treatabl
tmpsmx
subsequ
suppress
therapi
indic
microsporidiosi
microsporidia
intracellular
protozoan
due
hiv
aid
emerg
rel
obscur
pathogen
insect
fish
laboratori
anim
occupi
new
role
import
oi
human
cosmopolitan
emerg
pathogen
immunosuppress
includ
enterocytozoon
bienusi
enterocytozoon
septata
intestinali
enterocytozoon
cuniculi
enterocytozoon
hellem
well
pathogen
sever
genera
consid
chapter
entamoeba
histolytica
intestin
parasit
see
chapter
initi
associ
hiv
high
preval
men
sex
men
msm
despit
consider
evid
immun
amebiasi
requir
particip
cmi
evid
patient
hiv
infect
aid
like
develop
invas
diseas
giardia
lamblia
e
histolytica
high
preval
infect
g
lamblia
see
chapter
found
among
msm
studi
msm
perform
time
reveal
increas
preval
sever
giardiasi
patient
aid
sinc
evid
found
signific
effect
hiv
coinfect
although
studi
indic
higher
preval
giardiasi
hiv
seroposit
consist
find
therapi
giardiasi
peopl
aid
usual
success
patient
immunocompromis
well
immunocompet
refractori
standard
therapeut
regimen
giardiasi
may
well
refractori
standard
therapi
found
commonli
face
hiv
coinfect
blastocysti
homini
controversi
continu
exist
role
organ
caus
diarrheal
diseas
either
immunocompet
patient
hivinfect
peopl
blastocysti
homini
cosmopolitan
distribut
associ
tropic
balantidium
coli
inform
avail
whether
organ
serv
oi
hivinfect
peopl
evid
trematod
infect
sever
difficult
treat
hivinfect
peopl
subtl
interact
explor
schistosomiasi
see
chapter
studi
car
washer
work
shore
lake
victoria
kenya
popul
high
intens
exposur
mansoni
hiv
seropreval
approxim
provid
insight
bidirect
effect
coinfect
celldepend
granulomat
respons
schistosom
egg
shown
import
egg
migrat
venul
lumen
intestin
mous
model
diseas
might
therebi
expect
signific
suppress
egg
excret
effici
control
degre
infect
found
mansoniinfect
patient
presenc
hiv
coinfect
low
tcell
count
although
success
therapi
mansoni
infect
praziquantel
may
depend
host
antibodi
respons
praziquantel
efficaci
treat
schistosomiasi
hivinfect
cohort
given
schistosom
infect
like
preced
hiv
infect
individu
whether
praziquantel
equal
efficaci
individu
infect
hiv
first
remain
open
question
notabl
despit
similar
respons
therapi
individu
hiv
coinfect
low
cell
count
show
increas
suscept
reinfect
therapi
respons
appear
correl
blunt
immunolog
respons
success
drug
therapi
result
releas
parasit
antigen
individu
studi
hiv
haematobium
coinfect
zambia
led
find
mirror
find
mansoni
coinfect
individu
lower
egg
excret
praziquantel
retain
efficaci
face
hiv
coinfect
alter
resist
reinfect
haemotobium
seen
face
hiv
infect
tcell
count
perform
cohort
lack
evid
hivrel
diseas
thu
remain
possibl
mansoni
infect
resist
reinfect
haematobium
decreas
progress
hivaid
effect
schistosomiasi
hiv
evid
suggest
genit
schistosomiasi
due
haematobium
infect
risk
factor
hiv
transmiss
varieti
sexual
transmit
diseas
mucos
vulval
vagin
cervic
inflammatori
lesion
associ
femal
genit
schistosomiasi
like
compromis
antivir
barrier
mucosa
provid
cellular
milieu
allow
effici
viral
transmiss
replic
enhanc
viral
shed
correspondingli
male
genit
schistosomiasi
also
like
associ
increas
risk
hiv
transmiss
madagascar
haematobium
caus
inflamm
prostat
semin
vesicl
adolesc
adult
male
patient
analog
bacteri
urethr
chronic
inflamm
like
associ
increas
viral
shed
semen
hivcoinfect
individu
schistosomiasi
prime
exampl
chronic
tropic
infect
postul
enhanc
pathogenesi
hiv
schistosoma
mansoni
infect
act
power
induc
polar
murin
model
human
type
cytokin
environ
induc
mansoni
egg
significantli
suppress
cellmedi
viral
clearanc
experiment
model
found
impair
antigenspecif
immun
respons
mice
human
type
immunolog
respons
also
postul
favor
hiv
progress
due
preferenti
replic
hiv
cell
amplif
activationinduc
apoptosi
lymphocyt
type
cytokin
upregul
express
hiv
coreceptor
cell
monocytemacrophag
final
antigen
exposur
schistosomiasi
may
lead
sustain
upregul
hiv
replic
via
effect
chronic
immun
activ
consider
remain
theoret
inde
treatment
mansoni
infect
appear
reduc
plasma
hiv
load
coinfect
individu
cestod
unusu
manifest
cestod
infect
report
aid
patient
rapidli
expand
invas
ultim
lethal
abdomin
mass
patient
tcell
count
less
found
ribosom
dna
amplif
sequenc
due
yet
uncharacter
cestod
whether
repres
mere
fortuit
concurr
unusu
patholog
find
dramat
improv
diagnost
technolog
previou
rare
case
normal
host
occur
absenc
diagnosi
recognit
new
diseas
express
facilit
depend
immunosuppress
aid
patient
serv
sentinel
chicken
popul
larg
unclear
latter
interpret
favor
previou
similar
case
report
presum
dissemin
cestod
infect
face
immunosuppress
due
hodgkin
diseas
therapi
four
case
exuber
subcutan
diseas
due
larval
form
taenia
crassicep
report
aid
patient
best
one
previou
number
case
report
human
infect
crassisep
suggest
hiv
infect
risk
diseas
cestod
case
hepat
alveolar
echinococc
diseas
child
aid
describ
uncommon
featur
case
includ
remark
young
age
henc
short
incub
period
diseas
complet
lack
demonstr
parasitespecif
humor
cellular
immun
respons
final
case
neurocysticercosi
report
hivinfect
patient
number
sure
increas
given
increas
rate
hiv
infect
endem
area
frequenc
giant
cyst
racemos
form
diseas
remark
elev
report
case
perhap
reflect
role
cell
tissu
immun
solium
clinic
data
interact
hiv
cestod
infect
await
strongyloid
stercorali
nematod
implic
caus
oi
presenc
hiv
coinfect
intestin
parasit
strongyloid
stercorali
see
chapter
stercorali
appear
qualifi
oi
one
nematod
capabl
actual
multipli
especi
immunocompromis
human
host
capillaria
philippinensi
human
natur
host
also
multipli
intern
c
philippinensi
rare
quit
limit
geograph
distribut
report
coinfect
hivseroposit
peopl
see
chapter
one
way
immunosuppress
enhanc
strongyloid
infect
permit
stimul
increas
degre
normal
process
autoinfect
process
firststag
rhabditiform
larva
produc
adult
femal
worm
upper
small
bowel
transform
infect
filariform
larva
reinvad
intestin
wall
colon
perian
perin
area
massiv
upregul
autoinfect
process
result
hyperinfect
syndrom
develop
mani
adult
worm
product
larg
number
larva
dissemin
organ
clinic
pictur
domin
gramneg
bacteri
sepsi
mening
pneumonia
hyperinfect
usual
associ
immunosuppress
particularli
administr
corticosteroid
fact
list
immunosuppress
diseas
malign
benign
associ
hyperinfect
unifi
corticosteroid
common
denomin
treatment
steroid
much
alter
tcell
function
host
organ
defens
mechan
necessari
control
stercorali
human
identifi
even
direct
effect
steroid
femal
worm
reproduct
effici
postul
data
meager
strongyloid
initi
design
aid
oi
past
record
caus
hyperinfect
immunosuppress
five
year
later
becam
appar
hyperinfect
syndrom
encount
frequent
patient
aid
remov
list
oi
indic
aid
given
low
appreci
rate
strongyloidiasi
among
men
attend
vener
diseas
clinic
new
york
citi
aid
epidem
unit
state
develop
provid
clinic
evid
predisposit
aid
patient
hyperinfect
occur
avail
evid
make
extrem
unlik
misdiagnosi
underreport
relev
factor
sever
strongyloidiasi
hyperinfect
syndrom
promin
clinic
featur
often
fatal
untreat
like
associ
would
escap
notic
case
hyperinfect
syndrom
report
englishlanguag
literatur
even
among
case
presenc
hyperinfect
poorli
document
mani
diagnosi
oppos
suspicion
hyperinfect
syndrom
depend
demonstr
markedli
increas
number
filariform
larva
stool
multipl
larva
sputum
mere
presenc
filariform
larva
sputum
indic
exist
autoinfect
also
note
presenc
rhabditiform
larva
sputum
point
neither
autoinfect
hyperinfect
presenc
adult
femal
worm
lung
unfortun
confus
gastrointestin
diseas
hyperinfect
syndrom
embed
literatur
possibl
frequenc
sever
strongyloidiasi
complic
hiv
infect
much
higher
certain
area
tropic
infect
preval
medic
facil
lack
howev
absenc
associ
note
area
petithori
derouin
point
clinic
studi
aid
patient
central
africa
preval
strongyloidiasi
vari
mention
extraintestin
strongyloidiasi
similarli
report
brazil
estim
preval
strongyloid
infect
popul
paulo
find
parasit
aid
patient
show
evid
system
strongyloidiasi
similar
result
found
zambia
survey
urban
adult
kinshasa
congo
formerli
zair
detect
stercorali
intens
fecal
examin
singl
specimen
estim
infect
rate
popul
basi
posit
serolog
signific
differ
infect
rate
seroposit
seroneg
hiv
f
neva
unpublish
observ
taken
togeth
data
suggest
presenc
sever
clinic
diseas
due
stercorali
significantli
increas
patient
hiv
infect
aid
alon
recent
studi
shed
light
subject
care
quantit
number
proport
freeliv
adult
worm
directli
develop
larva
stool
cultur
reveal
surpris
neg
correl
tcell
count
proport
adult
worm
individu
infect
hiv
thu
advanc
immunosuppress
due
hiv
associ
paradox
suppress
direct
develop
larva
subtl
interact
increas
mean
gastrointestin
parasit
burden
slower
respons
therapi
may
miss
also
condit
cosegreg
hivaid
known
predispos
hyperinfect
syndrom
includ
use
steroid
given
pneumocysti
pneumonia
lymphoma
aid
inanit
seen
patient
chronic
diarrhea
untreat
oropharyng
esophag
candidiasi
slim
diseas
coinfect
human
tcell
lymphotrop
viru
type
htlvi
see
chapter
strongyloidiasi
import
oi
individu
infect
strongyloid
infect
suspect
cofactor
develop
acut
tcell
leukemia
tropic
spastic
paraparesi
asymptomat
carrier
htlvi
notabl
intraven
drug
use
risk
factor
infect
htlvi
hiv
intestin
helminthiasi
intestin
helminth
infect
ubiquit
lowincom
tropic
countri
although
helminth
appear
act
oi
aid
hypothes
immun
dysregul
associ
geohelminth
infect
may
alter
natur
histori
hiv
infect
unfavor
manner
hypothes
found
presenc
chronic
immun
activ
polar
chronic
helminth
infect
inde
demonstr
peripher
blood
cell
patient
intestin
helminth
infect
filari
infect
suscept
vitro
infect
hiv
cell
helminthuninfect
patient
overal
hypothesi
remain
unproven
howev
initi
studi
ethiopia
indic
hiv
viral
load
significantli
higher
individu
variou
helminth
infect
individu
without
helminth
correl
posit
parasit
load
well
decreas
elimin
worm
antiparasit
treatment
howev
similar
studi
perform
uganda
examin
far
larger
number
patient
convincingli
fail
replic
find
latter
studi
strongli
suggest
helminth
coinfect
associ
faster
progress
hiv
diseas
onchocerca
volvulu
among
filaria
effect
hiv
coinfect
studi
larg
cohort
patient
onchocerca
volvulu
infect
signific
epidemiolog
associ
found
two
infect
differ
efficaci
ivermectin
treatment
hivinfect
compar
uninfect
patient
arthropod
sarcopt
scabiei
var
homini
stand
alon
among
arthropod
crustacean
infest
human
caus
exacerb
diseas
presenc
hiv
infect
normal
host
scabi
usual
manifest
markedli
prurit
papular
vesicular
dermat
pathognomon
burrow
harbor
gravid
femal
excori
nodul
eczemat
impetigin
plaqu
may
also
found
rel
adult
mite
normal
present
norwegian
crust
scabi
seen
neurolog
impair
immunosuppress
patient
pruritu
often
absent
mild
lesion
consist
widespread
hyperkeratot
crust
scale
fissur
plaqu
nail
frequent
involv
patient
tend
heavili
infest
thousand
adult
mite
see
chapter
crust
scabi
report
complic
hiv
infect
tcell
count
report
case
less
typic
atyp
present
seen
latter
includ
pruritu
aid
crust
pruritu
prurit
papular
dermat
mimic
darier
diseas
psoriasi
secondari
sepsi
death
report
face
clinic
variabl
diagnosi
crust
scabi
hivseroposit
peopl
rest
appropri
clinic
suspicion
demonstr
heavi
infest
microscop
examin
skin
scrape
extraordinari
mite
load
patient
remark
contagi
combin
therapi
ivermectin
topic
benzyl
benzoat
perhap
permethrin
appear
treatment
choic
singledos
ivermectin
also
effect
prevent
transmiss
close
contact
despit
specul
earli
aid
pandem
evid
transmiss
hiv
arthropod
vector
prurit
papular
erupt
associ
hiv
infect
common
subsaharan
africa
etiolog
intens
prurit
lesion
attribut
exagger
immun
respons
arthropod
bite
hivinfect
individu
dissemin
infect
p
marneffei
dimorph
fungu
endem
southeast
asia
southern
china
see
chapter
emerg
import
oi
aid
patient
third
common
oi
hiv
diseas
northern
thailand
extrapulmonari
tuberculosi
cryptococc
mening
first
isol
infect
p
marneffei
rare
event
arriv
aid
pandem
southeast
asia
sinc
thousand
case
diagnos
primarili
southern
china
northern
thailand
hong
kong
taiwan
malaysia
vietnam
singapor
indonesia
myanmar
overwhelm
major
case
aid
patient
although
normal
host
also
known
develop
system
diseas
fungu
pronounc
intracountri
variat
infect
rate
northern
thailand
onefourth
aid
patient
suffer
diseas
wherea
southern
thailand
preval
less
environment
reservoir
p
marneffei
unknown
organ
isol
organ
fece
burrow
three
speci
bamboo
rat
geograph
rang
rodent
overlap
previous
mention
known
area
endem
diseas
p
marneffei
suggest
likelihood
fungu
also
endem
lao
cambodia
malaysia
whether
bamboo
rat
import
reservoir
human
infect
anoth
natur
host
unclear
evid
transmiss
rat
human
season
distribut
diagnosi
dissemin
diseas
aid
patient
suggest
reservoir
p
marneffei
expand
raini
season
exposur
soil
appear
key
factor
pathogenesi
diseas
due
p
marneffei
presum
analog
endem
system
mycos
involv
transmiss
inhal
secondari
system
dissemin
like
histoplasma
capsulatum
p
marneffei
intracellular
parasit
monocytemacrophag
murin
model
pulmonari
dissemin
infect
show
cell
play
central
role
control
infect
aid
patient
dissemin
diseas
associ
tcell
count
less
largest
clinic
seri
report
date
aid
patient
dissemin
p
marneffei
infect
provid
detail
inform
patient
onset
symptom
gener
sudden
intens
common
present
symptom
sign
fever
anemia
weight
loss
skin
lesion
frequent
sign
symptom
includ
cough
gener
lymphadenopathi
hepatomegali
diarrhea
common
cutan
manifest
gener
papular
rash
central
umbil
resembl
lesion
molluscum
contagiosum
predominantli
found
face
scalp
upper
extrem
occur
throughout
bodi
includ
palat
cutan
lesion
includ
papul
without
umbil
maculopapular
rash
subcutan
nodul
acnelik
lesion
follicul
chest
film
frequent
abnorm
diffus
reticulonodular
local
alveolar
infiltr
common
mean
durat
ill
prior
present
studi
week
incub
period
dissemin
diseas
unclear
percentag
patient
whose
diseas
result
reactiv
latent
infect
oppos
new
infect
reinfect
fact
reactiv
increas
immunosuppress
occur
support
sever
case
dissemin
diseas
report
nonendem
area
aid
patient
distant
histori
travel
endem
area
mani
patient
spent
littl
time
endem
area
indic
infect
p
marneffei
occur
rapidli
develop
clinic
activ
diseas
within
week
exposur
endem
area
report
children
vertic
transmit
hiv
infect
develop
diseas
first
month
year
life
demonstr
primari
infect
quickli
lead
dissemin
diseas
final
pronounc
season
variat
diseas
incid
impli
import
role
exogen
reinfect
express
diseas
p
marneffei
aid
patient
endem
area
mortal
rate
patient
dissemin
p
marneffei
infect
high
absenc
prompt
treatment
diagnosi
depend
high
index
suspicion
includ
care
histori
assess
possibl
resid
travel
endem
area
differenti
diagnosi
includ
tuberculosi
endem
fungi
cryptococcosi
cutan
lesion
may
mimic
aidsrel
molluscum
contagiosum
histoplasma
capsulatum
cryptococcu
neoforman
absenc
cutan
lesion
may
retard
diagnosi
regard
characterist
syndrom
hepat
diseas
absenc
skin
lesion
fever
hepatomegali
markedli
elev
serum
alkalin
phosphatas
level
note
presumpt
diagnosi
made
examin
wright
sstain
bone
marrow
aspir
lymph
node
aspir
touch
prepar
skin
biopsi
specimen
intracellular
extracellular
basophil
ellipt
yeastlik
organ
central
septat
oppos
bud
h
capsulatum
characterist
indirect
fluoresc
antibodi
reagent
develop
may
prove
use
differenti
p
marneffei
h
capsulatum
c
neoforman
tissu
characterist
intracellular
organ
detect
routin
blood
smear
previous
discuss
seri
definit
diagnosi
perform
cultur
p
marneffei
blood
even
absenc
routin
lysiscentrifug
cultur
skin
biopsi
bone
marrow
sputum
diagnost
antigenemia
test
may
prove
valuabl
rapid
diagnosi
develop
quantit
urinari
antigen
enzym
immunoassay
employ
rabbit
hyperimmun
igg
especi
promis
high
sensit
specif
demonstr
area
high
endemn
note
p
marneffei
infect
known
caus
falseposit
reaction
h
capsulatum
polysaccharid
antigen
immunoassay
current
serolog
assay
unlik
help
diagnosi
aid
patient
improv
sensit
may
provid
use
index
infect
amphotericin
b
mgkgday
week
follow
itraconazol
mg
twice
day
week
safe
effect
mild
moder
ill
patient
primari
therapi
itraconazol
may
reason
secondari
prophylaxi
mandatori
given
relaps
rate
within
month
absenc
placebocontrol
doubleblind
random
trial
show
secondari
prophylaxi
itraconazol
mg
daili
safe
effect
immun
reconstitut
result
success
respons
haart
discontinu
secondari
prophylaxi
probabl
safe
control
doubleblind
trial
primari
prophylaxi
itraconazol
mg
daili
thai
patient
aid
tcell
count
less
show
regimen
well
toler
effect
prevent
cryptococcosi
penicilliosi
surviv
benefit
found
studi
power
detect
surviv
advantag
dimorph
fungu
p
brasiliensi
caus
common
system
mycosi
latin
america
see
chapter
two
clinic
form
distinguish
normal
host
acut
subacut
juvenil
form
chronic
adult
form
acut
juvenil
diseas
occur
children
young
adult
account
small
minor
case
mark
rapid
cours
dissemin
involv
monocyt
macrophag
lymphoid
tissu
sever
suppress
cmi
chronic
adult
diseas
account
vast
major
case
slowli
progress
diseas
predominantli
older
men
patient
primari
clinic
patholog
manifest
pulmonari
nodular
infiltr
cavitari
lesion
progress
fibrosi
frequent
manifest
adult
diseas
includ
infiltr
ulcer
mucos
lesion
oroand
nasopharynx
polymorph
cutan
lesion
lymphadenopathi
adren
infiltr
infect
subclin
long
latenc
clearli
demonstr
mean
year
leav
endem
area
present
thought
cmi
respons
critic
host
defens
diseas
p
brasiliensi
clinic
experiment
evid
indic
paracoccidioidomycosi
associ
mark
abnorm
immun
function
suppress
cmi
respons
polyclon
bcell
activ
elev
plasma
ige
level
immunolog
perturb
common
sever
juvenil
diseas
revers
success
therapi
given
immunolog
paracoccidioidomycosi
one
might
expect
promin
oi
south
america
among
hiv
patient
histori
travel
fact
fewer
case
report
despit
presum
wide
preval
infect
coinfect
area
urban
brazil
possibl
reason
low
number
case
hivseroposit
patient
includ
prophylaxi
tmpsmx
activ
p
brasiliensi
use
ketoconazol
oropharyng
candidiasi
misdiagnosi
pcp
therapeut
respons
tmpsmx
lack
diagnosi
presenc
particularli
subtl
interact
hiv
p
brasiliensi
paracoccidioidomycosi
hivseroposit
peopl
primarili
acut
form
promin
involv
reticuloendotheli
system
howev
pulmonari
oral
mucos
involv
typic
chronic
form
often
coexist
although
publish
report
suggest
dissemin
diseas
may
occur
across
broad
rang
hivassoci
immunosuppress
tcell
count
less
report
norm
onethird
patient
paracoccidioidomycosi
present
anoth
opportunist
coinfect
frequent
oralesophag
candidiasi
tuberculosi
report
clinic
present
span
wide
spectrum
rel
indol
rapidli
progress
diseas
clinic
manifest
includ
prolong
fever
weight
loss
cough
dyspnea
gener
lymphadenopathi
hepatosplenomegali
skin
lesion
local
dissemin
maculopapular
nodular
ulcer
oral
lesion
ulcer
andor
nodular
osteoarticular
lesion
mening
diagnosi
patient
made
direct
examin
cultur
clinic
specimen
includ
skin
biopsi
lymph
node
aspir
biopsi
bone
marrow
aspir
csf
blood
sputum
also
examin
use
potassium
hydroxid
prepar
calcofluor
stain
immunofluoresc
pilot
wheel
cell
consist
numer
small
bud
surround
mother
cell
characterist
serolog
diagnost
help
mortal
report
case
diseas
hivseroposit
peopl
random
clinic
trial
perform
drug
commonli
use
treatment
p
brasiliensi
infect
sulfonamid
amphotericin
b
ketoconazol
itraconazol
even
normal
host
treatment
recommend
base
data
case
seri
comparison
histor
control
howev
data
fairli
compel
itraconazol
mgday
drug
choic
normal
host
publish
report
itraconazol
treatment
face
hiv
coinfect
scant
although
amphotericin
b
intraconazol
may
therapeut
role
play
amphotericin
b
probabl
use
initi
treatment
hiv
coinfect
patient
lifelong
suppress
therapi
necessari
itraconazol
seem
reason
choic
endem
dimorph
fungu
h
capsulatum
var
duboisii
local
western
central
africa
madagascar
see
chapter
normal
host
tend
caus
chronic
necrot
cutan
skelet
infect
dissemin
diseas
unusu
may
emerg
oi
aid
patient
increas
incid
african
histoplasmosi
report
studi
peopl
republ
congo
congo
republ
despit
rapid
increas
aidsrel
incid
cryptococc
diseas
diseas
manifest
report
hand
hivh
capsulatum
var
duboisii
coinfect
describ
literatur
howev
suggest
aid
patient
risk
sever
dissemin
diseas
diagnosi
direct
examin
clinic
specimen
cultur
yeast
form
larger
thicker
wall
h
capsulatum
var
capsulatum
amphotericin
b
itraconazol
therapeut
efficaci
dimorph
fungu
schenckii
worldwid
distribut
although
report
tropic
subtrop
area
america
see
chapter
highest
incid
diseas
thought
highland
mexico
southern
brazil
cutan
lymphocutan
diseas
common
extracutan
involv
includ
osteoarticular
diseas
pneumonia
mening
describ
normal
immunosuppress
host
hand
case
sever
dissemin
sporotrichosi
latestag
aid
describ
diffus
cutan
involv
norm
patient
also
present
cn
ocular
osteoarticular
splenic
bone
marrow
mucos
involv
appear
like
dissemin
sporothrix
becom
promin
oi
heavili
endem
area
respons
therapi
amphotericin
b
potassium
iodid
itraconazol
ketoconazol
variabl
problemat
amphotericin
b
probabl
use
initi
treatment
follow
lifelong
suppress
therapi
itraconazol
histoplasma
capsulatum
blastomyc
dermatitidi
coccidioid
immiti
system
mycos
endem
unit
state
caus
oi
aid
patient
obvious
distinctli
tropic
diseas
cover
indepth
elsewher
tropic
extent
respect
area
endem
deserv
brief
mention
howev
histoplasma
capsulatum
var
capsulatum
see
chapter
found
distinct
river
basin
system
worldwid
equat
progress
dissemin
histoplasmosi
common
aid
patient
endem
area
addit
promin
worldwid
focu
ohio
mississippi
river
valley
unit
state
case
report
central
south
america
caribbean
africa
southeast
asia
europ
diseas
caus
b
dermatitidi
origin
name
north
american
blastomycosi
clear
howev
distribut
fungu
far
cosmopolitan
see
chapter
blastomycosi
report
major
region
africa
concentr
southern
africa
like
underreport
occasion
case
report
central
south
america
middl
east
india
african
strain
b
dermatitidi
appear
antigen
distinct
north
american
strain
clinic
spectrum
likewis
appear
differ
african
case
promin
involv
bone
chronic
drain
sinus
dissemin
blastomycosi
uncommon
late
frequent
fatal
oi
patient
aid
unit
state
case
africa
expect
futur
coccidioid
immiti
endem
lower
sonoran
life
zone
unit
state
mexico
guatemala
hondura
colombia
venezuela
bolivia
paraguay
argentina
see
chapter
coccidioidomycosi
sever
often
fatal
diseas
patient
aid
low
tcell
count
present
diffus
focal
pulmonari
diseas
extrapulmonari
dissemin
uncommon
endem
area
third
common
oi
aid
patient
cryptococcu
neoforman
cryptococcosi
see
chapter
common
lifethreaten
fungal
infect
aid
patient
although
dissemin
c
neoforman
affect
almost
organ
system
hivinfect
peopl
mening
frequent
manifest
rel
common
manifest
includ
pneumonia
cutan
lesion
occur
commonli
count
fall
well
cryptococcosi
frequent
present
diagnosi
aid
excel
review
cryptococcosi
aid
avail
detail
inform
clinic
approach
ubiquit
oi
cryptococcu
neoforman
distribut
global
distribut
cryptococcu
oi
aid
global
well
region
differ
exist
preval
diseas
defin
clinic
autopsi
seri
preval
cryptococcosi
aid
patient
unit
state
estim
thailand
second
common
oi
tuberculosi
preval
differ
clinic
seri
africa
case
seri
preval
variabl
soweto
south
africa
kinshasa
former
zair
preval
autopsi
seri
similarli
vari
abidjan
divoir
uganda
overal
rate
diseas
africa
appear
higher
north
america
europ
interestingli
larg
retrospect
case
studi
london
found
significantli
higher
rate
extrapulmonari
cryptococc
diseas
african
attend
hiv
clinic
nonafrican
attend
clinic
data
case
seri
estim
preval
cryptococcosi
mexico
haiti
brazil
patient
cryptococcu
aidsdefin
diagnosi
cryptococcu
neoforman
exist
two
varieti
c
neoforman
var
neoforman
c
neoforman
var
gatti
inhabit
differ
ecolog
nich
c
neoforman
var
neoforman
associ
soil
contamin
bird
excrement
c
neoforman
var
gatti
uniqu
poorli
understood
associ
tree
eucalyptu
camaldulensi
wherea
c
neoforman
var
gatti
predominantli
tropic
subtrop
distribut
c
neoforman
var
neoforman
occur
worldwid
note
although
cryptococcosi
due
c
neoforman
var
gatti
occur
regular
normal
host
region
varieti
endem
case
cryptococcosi
aid
patient
almost
exclus
due
c
neoforman
var
neoforman
pneumocysti
jiroveci
previous
p
carinii
f
spp
throughout
world
almost
univers
serolog
evid
exposur
age
year
p
jiroveci
ubiquit
fungu
see
chapter
preval
antibodi
specif
p
jiroveci
antigen
vari
howev
suggest
exposur
antigen
differ
strain
differ
area
world
mirror
genet
studi
reveal
strain
differ
organ
pcp
pneumocysti
carinii
pneumonia
base
prior
terminolog
remain
frequent
seriou
oi
unit
state
europ
despit
dramat
decreas
incid
due
introduct
haart
prior
haart
occur
patient
count
less
per
year
patient
overal
absenc
prophylaxi
haart
far
wide
avail
much
tropic
pcp
preval
appear
high
expect
among
aid
patient
central
south
america
asia
interestingli
howev
incid
pcp
adult
aid
patient
africa
thought
far
lower
seen
prehaart
era
industri
countri
adult
clinic
seri
africa
shown
preval
rate
studi
includ
bronchoscopi
diagnosi
describ
rate
highest
figur
obtain
percentag
acidfast
bacillusneg
pneumonia
autopsi
seri
rate
reason
lower
rate
pcp
africa
unclear
possibl
explan
includ
less
environment
exposur
p
jiroveci
exposur
differ
strain
p
jiroveci
differ
host
suscept
earlier
death
tropic
patient
aid
due
exposur
virul
organ
diagnost
difficulti
hostspecif
differ
suscept
exposur
p
jiroveci
appear
similar
worldwid
note
previous
exist
genet
antigen
distinct
human
strain
like
howev
pediatr
pcp
rate
aid
patient
africa
quit
similar
industri
north
inde
approxim
onethird
hivinfect
infant
africa
die
first
year
life
pcp
thought
respons
death
demis
virul
pathogen
prior
clinic
pcp
may
well
occur
adult
pcp
tend
occur
earli
cours
hiv
diseas
north
american
infant
perhap
initi
exposur
high
preval
cryptococc
diseas
seri
thought
occur
similar
level
immunosuppress
suggest
complet
answer
diagnost
difficulti
may
also
play
role
well
address
sever
cite
studi
clinic
present
pcp
tropic
appear
similar
industri
north
frequent
coinfect
tuberculosi
may
obscur
diagnosi
multipl
review
clinic
approach
pcp
aid
avail
fungi
predominantli
tropic
fungi
agent
maduromycosi
lobomycosi
rhinosporidiosi
subcutan
zygomycosi
may
prove
caus
opportunist
infect
aid
patient
report
isol
case
report
infect
due
varieti
unusu
fungi
aid
patient
publish
review
kaplan
colleagu
vartivarian
associ
perfect
schell
may
inde
prove
oi
even
predominantli
tropic
oi
firm
data
lack
common
occurr
superfici
invas
infect
candida
grow
problem
aspergillu
infect
neutropen
longterm
survivor
latestag
aid
beyond
scope
chapter
although
tuberculosi
see
chapter
usual
perceiv
tropic
diseas
preval
mortal
diseas
tropic
far
surpass
industri
countri
temper
zone
approxim
onethird
million
peopl
live
hiv
worldwid
coinfect
tuberculosi
live
subsaharan
africa
develop
countri
patient
hiv
infect
develop
activ
tuberculosi
contrast
unit
state
patient
aid
tuberculosi
countri
subsaharan
africa
tuberculosi
patient
hivseroposit
tuberculosi
lead
caus
death
among
peopl
hiv
infect
account
onethird
aid
death
worldwid
introduct
haart
decreas
death
oi
tuberculosi
among
peopl
live
hiv
worldwid
affluent
countri
develop
countri
howev
haart
remain
avail
small
minor
need
tuberculosi
one
earliest
oi
link
hiv
infect
mani
develop
countri
common
seriou
oi
associ
hiv
tuberculosi
rel
earli
complic
hiv
occur
aidsdefin
ill
hivinfect
patient
sever
relev
cmi
function
includ
lymphocyt
prolifer
cytolyt
tcell
activ
shown
significantli
suppress
hivinfect
patient
tuberculosi
addit
host
respons
may
impair
includ
elabor
cytokin
tcell
count
suppress
tuberculosi
patient
without
hiv
coinfect
rise
therapi
tuberculosi
although
consequ
coinfect
appear
advers
affect
tubercul
process
mainli
also
evid
albeit
somewhat
controversi
deleteri
effect
tuberculosi
cours
hiv
diseas
sever
studi
shown
vitro
hiv
replic
enhanc
blood
monocyt
patient
activ
pulmonari
tuberculosi
lymph
node
mononuclear
cell
cell
hivinfect
purifi
protein
deriv
ppd
skin
testposit
patient
stimul
ppd
hand
enhanc
suppress
hiv
replic
monocyt
report
vitro
infect
tuberculosi
vivo
plasma
viral
load
shown
higher
hivinfect
patient
activ
tuberculosi
hivinfect
peopl
without
activ
tuberculosi
remain
high
throughout
cours
treatment
howev
whether
tuberculosi
increas
hiv
load
whether
higher
hiv
load
realli
marker
increas
risk
tuberculosi
coinfect
patient
remain
unclear
similarli
although
tuberculosi
associ
reduc
surviv
hivinfect
patient
direct
indirect
line
evid
suggest
relat
may
well
directli
causal
one
prophylaxi
diagnosi
treatment
tuberculosi
presenc
hiv
coinfect
dealt
depth
elsewher
certain
issu
particular
relev
tropic
explor
primari
prevent
therapi
tuberculosi
isoniazid
shown
effect
hivinfect
individu
regardless
tuberculin
statu
metaanalys
suggest
reduct
tuberculosi
incid
posit
tuberculin
test
reduct
approxim
among
treat
individu
whounaid
recommend
primari
prevent
therapi
given
ppdposit
hivinfect
individu
activ
tuberculosi
set
may
feasibl
ppd
test
whounaid
recommend
primari
prevent
therapi
consid
live
popul
preval
tubercul
infect
estim
healthcar
worker
household
contact
tuberculosi
patient
prison
miner
group
high
risk
acquisit
transmiss
tuberculosi
although
studi
shown
shortcours
therapi
rifampin
plu
pyrazinamid
month
efficaci
month
isoniazid
prevent
activ
tuberculosi
hivinfect
adult
posit
tuberculin
skin
test
side
effect
associ
regimen
gener
popul
appar
hivinfect
popul
left
isoniazid
prophylact
agent
choic
treatment
activ
suscept
tuberculosi
firstlin
drug
effect
cure
tuberculosi
hivinfect
hivuninfect
individu
absenc
haart
howev
death
rate
treatment
tuberculosi
higher
peopl
hiv
infect
alon
mainli
due
oi
conflict
report
increas
rate
tuberculosi
recurr
face
hiv
coinfect
provid
suffici
evid
increas
durat
treatment
combin
haart
tuberculosi
treatment
difficult
sever
reason
overlap
toxic
profil
antituberculosi
antiretrovir
drug
drug
interact
nonadher
complic
treatment
regimen
import
problem
possibl
paradox
reaction
reaction
includ
transient
worsen
appear
new
sign
symptom
radiograph
manifest
tuberculosi
within
day
week
initi
antiretrovir
treatment
reaction
like
due
immun
reconstitut
may
particularli
sever
haart
start
soon
initi
treatment
activ
tuberculosi
center
diseas
control
prevent
cdc
american
thorac
societi
recommend
tuberculosi
treatment
continu
previous
start
haart
avoid
initi
haart
tuberculosi
therapi
time
alway
start
tuberculosi
therapi
first
delay
haart
initi
first
month
tuberculosi
therapi
complet
mani
world
children
vaccin
bacil
bcg
risk
benefit
ratio
vaccin
sure
alter
presenc
hiv
infect
risk
side
case
report
local
dissemin
diseas
due
bcg
children
adult
dissemin
diseas
host
devast
event
overal
mortal
usual
occur
immunosuppress
patient
whether
local
dissemin
diseas
due
hiv
coinfect
cite
case
remain
unclear
howev
side
potenti
benefit
efficaci
bcg
hivinfect
popul
unclear
data
support
lack
benefit
vaccin
hivseroposit
children
benefit
childhood
vaccin
hivseroposit
adult
protect
diseas
due
tuberculosi
publish
benefit
would
like
multipli
much
higher
risk
tuberculosi
face
concurr
hiv
infect
furthermor
data
suggest
benefici
effect
earli
bcg
vaccin
mortal
caus
hivuninfect
children
suggest
measur
benefit
hivseroposit
patient
need
broader
mere
prevent
tuberculosi
bcg
vaccin
remain
expand
programm
immun
epi
recommend
bcg
given
children
asymptomat
hiv
infect
area
high
risk
tuberculosi
infect
bcg
recommend
symptomat
hiv
infect
defin
aid
area
risk
tuberculosi
minim
bcg
recommend
peopl
known
suspect
infect
hiv
use
bcg
hivseroposit
patient
consid
contraind
us
public
health
serviceinfecti
diseas
societi
america
usphsidsa
guidelin
advisori
committe
immun
practic
acip
avium
complex
mac
see
chapter
consist
serovar
two
mycobacterium
speci
mycobacterium
avium
mycobacterium
intracellular
mac
bacteria
ubiquit
organ
commonli
isol
soil
natur
sourc
water
tap
water
domest
wild
anim
worldwid
mac
isol
aid
patient
avium
serovar
dissemin
diseas
due
avium
common
system
bacteri
infect
aid
patient
industri
north
occur
aid
patient
unit
state
diseas
occur
almost
exclus
tcell
count
less
frequent
tcell
count
less
pathogenesi
dissemin
avium
infect
aid
thought
involv
primari
infect
reinfect
oppos
reactiv
initi
colon
respiratori
gastrointestin
tract
follow
widespread
dissemin
system
diseas
mark
highgrad
mycobacteremia
almost
exclus
monocyt
impress
tissu
burden
bacteria
remark
featur
avium
tropic
appar
virtual
absenc
dissemin
diseas
aid
patient
mani
area
predominantli
subsaharan
africa
none
blood
cultur
sever
ill
patient
advanc
aid
uganda
posit
avium
mycobacteri
sputum
cultur
hivseroposit
seroneg
patient
hospit
found
posit
avium
none
blood
cultur
hivposit
adult
inpati
divoir
grew
avium
wherea
grew
tuberculosi
none
diagnost
lymph
node
biopsi
hivseroposit
african
patient
histolog
characterist
dissemin
avium
infect
reason
appar
absenc
dissemin
diseas
due
avium
area
tropic
unclear
decreas
preval
pcp
mani
explan
propos
includ
less
exposur
avium
exposur
differ
less
pathogen
variant
avium
differ
host
suscept
greater
acquir
immun
mycobacteria
earlier
death
virul
pathogen
diagnost
difficulti
overal
exposur
mac
organ
like
similar
environment
isol
mac
occur
similar
greater
frequenc
congo
uganda
unit
state
skin
test
survey
suggest
similar
frequenc
exposur
mac
econom
develop
develop
countri
pipe
water
system
unit
state
europ
higher
frequenc
mac
isol
howev
econom
condit
may
lead
greater
exposur
maccontain
droplet
via
showerhead
econom
develop
countri
differ
howev
unlik
lead
essenti
total
absenc
diseas
countri
uganda
exposur
differ
avium
serovar
strain
may
well
import
data
serotyp
african
clinic
strain
scarc
preliminari
data
suggest
african
clinic
isol
distinguish
european
american
isol
restrict
fragment
length
polymorph
analysi
possibl
underli
genet
differ
host
suscept
beli
similar
rate
dissemin
avium
infect
present
diagnosi
african
nonafrican
aid
patient
london
clinic
greater
acquir
immun
mycobacteri
diseas
bcg
vaccin
prior
infect
tuberculosi
may
exist
report
bcg
coverag
ppd
reactiv
uganda
seem
unlik
explain
lack
dissemin
mac
diseas
earlier
death
due
greater
environment
presenc
greater
latent
infect
virul
pathogen
may
occur
unlik
entir
explan
patient
mani
previous
mention
studi
clinic
latestag
aid
final
design
sever
previou
studi
make
assert
central
problem
one
lack
diagnost
sophist
unten
data
await
mycobacterium
lepra
caus
agent
leprosi
see
chapter
incred
slowgrow
parasit
monocytemacrophag
compar
purpos
may
use
recal
leishmania
infect
similar
cell
promin
opportunist
pathogen
patient
hiv
infect
import
cmi
leprosi
leishmaniasi
emphas
turk
bryceson
detail
comparison
skin
lesion
histopatholog
diseas
moreov
immunopatholog
infect
similar
view
widespread
preval
leprosi
tropic
subtrop
immunosuppress
effect
hiv
aid
leprosi
would
expect
becom
readili
appar
littl
evid
interact
fact
comprehens
analysi
possibl
interact
hivaid
leprosi
luca
conclud
leprosi
appear
anoth
miss
infect
aid
quantit
measur
immun
unrespons
leprosi
count
aid
indic
clinic
progress
howev
gener
agreement
tuberculoid
form
diseas
character
wellorgan
granuloma
biopsi
skin
lesion
lepromin
reaction
organ
paucibacillari
patient
lepromat
leprosi
neg
lepromin
skin
test
biopsi
skin
lesion
lack
granulomat
respons
show
larg
number
organ
multibacillari
way
advers
effect
hiv
infect
leprosi
could
manifest
includ
increas
diseas
infect
ratio
shift
toward
multibacillari
diseas
alter
respons
antileprosi
chemotherapi
cours
presenc
leprosi
may
also
enhanc
hiv
infect
sever
studi
examin
posit
serolog
hiv
newli
diagnos
leprosi
case
one
report
rural
hospit
zambia
found
higher
preval
reactor
compar
blood
donor
surgic
patient
vs
number
small
control
adequ
match
larger
studi
hiv
seropreval
northwest
tanzania
new
leprosi
case
compar
control
found
presenc
hiv
antibodi
significantli
associ
multibacillari
diseas
fact
associ
base
five
hivposit
case
multibacillari
diseas
illustr
complex
epidemiolog
analysi
diseas
leprosi
anoth
comparison
seroposit
hiv
carri
among
new
case
leprosi
match
age
sex
district
resid
control
uganda
signific
differ
overal
posit
rate
found
case
vs
control
posit
hiv
reaction
frequent
among
multibacillari
case
differ
clinic
associ
note
zambia
leprosi
patient
activ
neuriti
suggest
hivposit
case
poorer
recoveri
nerv
function
control
treatment
steroid
factor
consid
evalu
report
hivaid
leprosi
patient
greater
likelihood
falseposit
serolog
reaction
one
posit
band
hiv
antigen
western
blot
commonli
found
sever
hundr
sera
northern
india
absenc
posit
enzymelink
immunosorb
assay
elisa
anoth
report
claim
sera
indonesia
sera
somalia
gave
posit
hiv
elisa
neg
western
blot
attribut
leprosi
appear
strike
evid
hiv
infect
advers
effect
cours
leprosi
suggest
sever
report
cite
previous
multibacillari
diseas
may
develop
influenc
hiv
infect
howev
sever
featur
leprosi
may
tend
obscur
interact
hiv
infect
infect
chronic
slow
progress
may
simpli
take
time
recogn
influenc
one
leprosi
predominantli
rural
infect
involv
peopl
yet
caught
ravag
hiv
aid
patient
aid
tropic
may
surviv
long
enough
display
interact
leprosi
final
patient
earli
stage
leprosi
rel
subtl
clinic
manifest
physician
urban
environ
may
familiar
therefor
may
go
realiz
note
haartassoci
immun
reconstitut
may
trigger
injuri
inflammatori
reaction
treat
patient
coinfect
leprosi
nontubercul
mycobacteria
diseas
due
mycobacterium
genavens
see
chapter
mimic
due
avium
caus
dissemin
diseas
aid
patient
low
tcell
count
mean
pathogenesi
appear
involv
initi
gastrointestin
colon
follow
dissemin
import
environment
reservoir
unclear
pet
bird
extens
gastrointestin
tract
involv
organ
may
also
present
tap
water
geograph
rang
diseas
begin
defin
case
report
north
america
europ
australia
common
present
symptom
sign
fever
weight
loss
abdomin
pain
chronic
diarrhea
lymphadenopathi
hepatosplenomegali
pseudowhippl
diseas
anemia
imag
spleen
may
suggest
splenic
abscess
diffus
nodular
infiltr
may
seen
lung
patholog
involv
organ
fill
histiocyt
pack
acidfast
bacilli
diagnosi
establish
isol
genavens
normal
steril
site
blood
bone
marrow
lymph
node
spleen
specif
diagnosi
confound
fastidi
growth
requir
organ
primari
isol
solid
media
difficult
growth
liquid
broth
may
sensit
definit
identif
demand
pcr
techniqu
clear
implic
signific
percentag
case
ascrib
dissemin
avium
like
due
genavens
data
treatment
retrospect
therapi
appear
associ
improv
symptom
surviv
multidrug
regimen
includ
clarithromycin
appear
associ
best
clinic
respons
aid
pandem
mycobacterium
kansasii
known
primarili
caus
chronic
pulmonari
diseas
resembl
tuberculosi
lung
underli
damag
mycobacterium
kansasii
second
mac
among
nontubercul
mycobacteria
caus
diseas
hivinfect
patient
unit
state
although
kansasii
report
caus
pulmonari
diseas
area
world
case
report
hiv
coinfect
north
america
europ
howev
coinfect
may
especi
preval
gold
mine
transvaal
south
africa
hivinfect
individu
diseas
due
kansasii
tuberculosi
similar
clinic
radiolog
characterist
major
differ
epidemiolog
prognost
implic
kansasii
diseas
tend
occur
later
cours
hiv
infect
mean
tcell
count
time
present
approxim
present
pulmonari
diseas
alon
dissemin
diseas
incid
industri
countri
plummet
haart
era
nontubercul
mycobacteria
differenti
colon
contamin
diseas
problemat
mere
colon
respiratori
tract
kansasii
appear
infrequ
aid
patient
howev
pulmonari
isol
taken
serious
despit
rel
vitro
resist
isoniazid
recommend
therapi
isoniazid
rifampin
ethambutol
therapi
clearli
alter
surviv
patient
pulmonari
diseas
dissemin
diseas
particularli
poor
prognosi
first
describ
mycobacterium
malmoens
uncommon
caus
pulmonari
diseas
resembl
tuberculosi
environment
reservoir
unknown
persontoperson
transmiss
never
document
multisystem
diseas
bacteremia
rare
occur
presenc
profound
immunosuppress
includ
sever
patient
aid
low
tcell
count
pulmonari
gastrointestin
diseas
along
bacteremia
usual
vitro
suscept
test
correl
well
clinic
respons
best
regimen
pulmonari
diseas
nonimmunosuppress
patient
appear
isoniazid
rifampin
ethambutol
optim
therapi
aid
patient
unclear
mycobacterium
haemophilum
caus
local
lymphaden
immunolog
healthi
children
cutan
osteoarticular
rare
pulmonari
dissemin
diseas
immunocompromis
patient
sever
case
report
aid
patient
cutan
lesion
includ
furuncl
abscess
papul
vesicl
deep
ulcer
lesion
usual
diffus
often
extrem
cultur
demand
supplement
media
iron
sourc
vitro
suscept
data
scatter
clinic
report
suggest
rifampin
plu
ciprofloxacin
reason
empir
therapi
agent
good
activ
includ
amikacin
ciprofloxacin
clarithromycin
environment
sourc
mode
infect
unclear
sever
mycobacteria
demonstr
suspect
caus
opportunist
diseas
aid
patient
includ
mycobacterium
fortuitum
primari
pulmonari
diseas
dissemin
diseas
cervic
lymphaden
mening
mycobacterium
marinum
dissemin
cutan
system
dissemin
diseas
mycobacterium
celatum
pulmonari
dissemin
diseas
mycobacterium
xenopi
dissemin
diseas
pulmonari
diseas
pulmonari
colon
mycobacterium
gordona
pulmonari
cutan
dissemin
diseas
mycobacterium
scrofulaceum
dissemin
diseas
mycobacterium
bovi
dissemin
diseas
mycobacterium
simia
dissemin
diseas
along
genit
inflammatori
ulcer
diseas
syphili
see
chapter
implic
cofactor
hiv
transmiss
mani
case
report
suggest
hiv
infect
alter
cours
diseas
treponema
pallidum
presenc
concurr
hiv
infect
syphili
thought
progress
frequent
rapidli
neurosyphili
lead
increas
incid
meningit
manifest
neurosyphili
lead
increas
frequenc
malign
secondari
syphili
ulcer
lesion
promin
system
symptom
less
amen
success
therapi
standard
regimen
assess
clinic
serolog
measur
includ
lack
appropri
nontreponem
titer
reduct
serolog
relaps
concern
base
larg
case
report
retrospect
studi
amplifi
disconcert
find
pallidum
invas
cn
earli
syphili
hivinfect
patient
earli
invas
cn
occur
equal
frequent
hivseroposit
seroneg
peopl
howev
atyp
cours
syphili
describ
previous
wellknown
preaid
era
knowledg
actual
frequenc
rel
signific
event
await
welldesign
prospect
studi
three
studi
provid
evid
clinic
present
clinic
serolog
respons
treatment
syphili
may
appreci
alter
hiv
coinfect
major
caveat
studi
mean
level
immunosuppress
patient
studi
assess
tcell
count
sever
furthermor
number
patient
involv
rel
small
thu
clinic
cours
syphili
face
sever
hivinduc
immunosuppress
may
fact
exacerb
respons
convent
therapi
may
lead
infrequ
occurr
seriou
advers
treatment
outcom
clinic
approach
hiv
patient
infect
cosmopolitan
sexual
transmit
diseas
std
thoroughli
discuss
elsewher
like
continu
evolv
whether
hiv
infect
deleteri
effect
cours
nonvener
endem
treponematos
see
chapter
unknown
effect
postul
analog
syphili
effect
hiv
concurr
infect
borrelia
speci
caus
relaps
fever
report
see
chapter
whether
lyme
diseas
follow
unusu
cours
hivinfect
peopl
unclear
final
initi
observ
suggest
leptospirosi
see
chapter
run
similar
cours
patient
coinfect
hiv
among
rickettsia
relat
organ
coxiella
burnetii
ehrlichia
organ
suspect
exacerb
concurr
hiv
infect
notabl
pathogen
oblig
intracellular
parasit
monocyt
macrophag
q
fever
see
chapter
worldwid
distribut
respons
pathogen
c
burnetii
live
multipli
phagolysosom
monocytemacrophag
parasit
host
defens
infect
appear
depend
specif
tcell
activ
microbicid
effector
function
infect
cell
radiat
cyclophosphamid
corticosteroid
pregnanc
led
reactiv
diseas
anim
model
case
seri
suggest
patient
immunocompromis
due
varieti
caus
includ
leukemia
hodgkin
diseas
bone
marrow
renal
transplant
alcohol
suscept
symptomat
acut
relaps
chronic
diseas
c
burnetii
rational
expect
frequent
seriou
diseas
hivinfect
patient
clear
data
less
studi
southern
franc
demonstr
threefold
higher
preval
antibodi
c
burnetii
hivseroposit
peopl
suggest
increas
rate
transmiss
hivinfect
peopl
found
seropreval
studi
pari
spain
central
african
republ
given
differenti
preval
risk
factor
acquisit
hiv
infect
studi
contradictori
data
strongli
suggest
c
burnetii
bloodborn
intraven
drug
use
risk
transmiss
two
studi
southern
europ
suggest
hiv
infect
lead
higher
diseaseinfect
ratio
c
burnetii
retrospect
serolog
studi
patient
acut
q
fever
area
spain
high
incid
hiv
c
burnetii
infect
reveal
overrepresent
hivinfect
peopl
howev
clinic
featur
q
fever
appear
vari
hivinfect
uninfect
host
howev
definit
statement
await
prospect
studi
sever
immunosuppress
aid
patient
human
monocyt
ehrlichiosi
hme
caus
tickborn
rickettsialik
agent
e
chaffeensi
acut
febril
ill
associ
leukopenia
thrombocytopenia
hepat
enzym
abnorm
case
report
infect
e
chaffeensi
see
chapter
unit
state
report
infect
mali
support
much
wider
distribut
diseas
howev
hme
appear
aidsrel
oi
report
hospit
case
high
rate
complic
mortal
approxim
compar
estim
case
fatal
rate
hme
absenc
hiv
patient
fatal
diseas
tcell
count
less
patient
less
mortal
rate
eight
report
case
diseas
caus
e
ewingii
relat
tickborn
agent
seven
occur
patient
immun
defici
includ
four
hiv
infect
suspicion
thu
strong
e
ewingii
opportunist
pathogen
set
hiv
infect
case
infect
tickborn
agent
human
granulocyt
ehrlichiosi
face
hiv
infect
appear
report
evid
implic
spot
fever
typhu
group
rickettsia
clinic
signific
interact
hiv
although
neither
mortal
morbid
rocki
mountain
spot
fever
chang
hiv
coinfect
infect
overlook
favor
defin
oi
differenti
diagnosi
febril
ill
hivseroposit
patient
prospect
studi
scrub
typhu
due
orientia
formerli
rickettsia
tsutsugamushi
reveal
increas
clinic
sever
time
present
hivinfect
patient
median
tcell
count
interestingli
rickettsemia
occur
significantli
less
often
hivseroposit
patient
neither
rel
preval
infect
respons
treatment
address
studi
brucella
caus
system
diseas
worldwid
brucella
speci
facult
intracellular
parasit
infect
multipli
macrophag
see
chapter
cmi
respons
particularli
activ
monocytemacrophag
antigenspecif
cell
import
host
resist
despit
meager
publish
data
coinfect
support
signific
effect
hiv
infect
brucella
fact
prior
aid
pandem
two
case
brucellosi
immunocompromis
host
hairi
cell
leukemia
igm
defici
report
retrospect
seropreval
studi
found
signific
associ
brucella
serolog
hiv
serolog
cohort
femal
sex
worker
kenya
preval
antibodi
pathogen
high
hiv
brucella
clinic
cours
brucellosi
report
case
concurr
hiv
infect
outsid
spectrum
diseas
seen
normal
host
definit
data
interact
two
pathogen
await
care
prospect
studi
melioidosi
see
chapter
appear
behav
aidsrel
oi
diseas
endem
southeast
asia
particularli
northern
thailand
preval
aid
high
one
case
fatal
recrudesc
bacterem
diseas
hivseroposit
person
report
howev
clinic
seri
thailand
silent
regard
presenc
melioidosi
aid
patient
studi
bloodstream
infect
hospit
northern
thailand
report
similar
proport
b
pseudomallei
isol
hivinfect
uninfect
patient
sever
enter
bacteri
infect
report
caus
diseas
greater
sever
invas
chronic
recurr
presenc
hiv
coinfect
enterotoxigen
e
coli
describ
caus
sever
diseas
hivseroposit
patient
shigella
speci
salmonella
campylobact
listeria
monocytogen
implic
caus
sever
relaps
diseas
presenc
hiv
data
tropic
enter
bacteri
pathogen
scant
studi
slim
diseas
enteropath
aid
reveal
enter
bacteri
caus
case
preval
certain
enter
pathogen
campylobact
vibrio
enteropathogen
e
coli
tropic
accur
assess
detect
requir
use
special
media
experienc
laboratori
personnel
case
less
fastidi
organ
easier
detect
salmonella
spp
phenomenon
bacteremia
nontyphoid
organ
note
tropic
africa
sinc
bacteremia
shigella
spp
probabl
occur
commonli
patient
hiv
diseas
associ
may
expect
occur
tropic
well
report
evid
suggest
cholera
alter
presenc
hiv
although
gastric
secretori
failur
occur
commonli
aid
may
lead
greater
suscept
infect
vibrio
cholera
note
although
live
oral
cholera
vaccin
consid
contraind
peopl
hiv
infect
usphsidsa
work
group
shown
safe
immunogen
hivinfect
adult
mali
detail
associ
hiv
enter
bacteri
infect
includ
therapi
present
chapter
review
elsewher
bacteria
although
data
hiv
infect
epidem
meningococc
mening
provid
evid
signific
interact
studi
suggest
hiv
infect
may
risk
factor
sporad
meningococc
diseas
interact
hiv
bacillu
anthraci
yersinia
pesti
report
global
endem
bartonella
speci
bartonella
hensela
bartonella
quintana
see
chapter
caus
acut
persist
bacteremia
well
local
tissu
infect
includ
bacillari
angiomatosi
bacillari
peliosi
microscop
abscess
format
lymphaden
primarili
aid
patient
immunocompromis
peopl
close
relat
speci
bartonella
bacilliformi
geograph
restrict
andean
river
valley
caus
similar
spectrum
diseas
includ
acut
persist
bacteremia
hemangiomat
nodul
resembl
seen
bacillari
angiomatosi
immunolog
normal
host
see
chapter
case
coinfect
hiv
b
bacilliformi
appear
report
none
virus
along
parasit
form
tradit
focu
angloamerican
specialti
tropic
medicin
report
caus
uniqu
preval
sever
unusu
diseas
peopl
infect
hiv
signific
interact
well
document
hiv
bunyavirus
hantavirus
phlebovirus
arenavirus
alphavirus
filovirus
part
cours
may
function
lack
suffici
experi
coinfect
agent
among
flavivirus
two
uncontrol
seri
patient
st
loui
enceph
texa
suggest
possibl
ratio
diseas
infect
cours
symptomat
diseas
worsen
presenc
hiv
infect
insuffici
data
determin
whether
hiv
alter
cours
yellow
fever
case
report
mortal
absenc
coinfect
west
nile
viru
infect
singl
case
report
dengu
infect
singl
case
report
interestingli
case
report
dengu
coinfect
suggest
dengu
fever
like
acut
measl
scrub
typhu
may
lead
revers
suppress
hiv
replic
liveattenu
yellow
fever
vaccin
given
infect
hiv
theoret
risk
vaccineinduc
enceph
andor
hepat
damag
due
prolong
viremia
immunodefici
hand
case
postvaccini
enceph
multipl
organ
failur
yellow
fever
vaccineassoci
viscerotrop
diseas
yelavd
report
presum
immunocompet
patient
denomin
approxim
million
peopl
vaccin
note
vaccine
develop
yelavd
undergon
thymectomi
thymoma
rais
concern
defici
thymic
function
may
permit
fatal
vaccineinduc
viral
infect
singl
case
also
report
fatal
myeloenceph
vaccin
thai
man
asymptomat
hiv
infect
albeit
low
tcell
count
high
viral
load
approxim
asymptomat
hivseroposit
us
militari
personnel
receiv
yellow
fever
vaccin
prior
introduct
routin
hiv
screen
advers
effect
detect
r
redfield
person
commun
small
publish
seri
travel
suggest
safeti
variabl
efficaci
yellow
fever
vaccin
hiv
seroposit
without
sever
immunosuppress
immunogen
yellow
fever
vaccin
note
sever
reduc
absenc
signific
advers
event
hivinfect
children
divoir
tsai
person
commun
recommend
use
yellow
fever
vaccin
hivseroposit
patient
asymptomat
remain
part
epi
pend
studi
yellow
fever
vaccin
recommend
symptomat
hivinfect
patient
acip
recommend
hivinfect
peopl
without
aid
symptomat
manifest
hiv
infect
laboratoryestablish
verif
adequ
immun
function
avoid
potenti
exposur
yellow
fever
offer
choic
vaccin
given
appar
reduc
vaccin
effici
neutral
antibodi
titer
probabl
measur
prior
travel
travel
requir
oppos
actual
risk
infect
reason
vaccin
asymptomat
hivinfect
person
vaccin
waiver
letter
may
accept
border
obtain
travel
avoid
area
transmiss
travel
area
essenti
conscienti
avoid
mosquito
exposur
prudent
measl
viru
see
chapter
caus
annual
mortal
tropic
far
excess
due
tradit
tropic
diseas
virus
fact
worldwid
yearli
mortal
due
measl
rival
among
singl
pathogen
falciparum
malaria
tuberculosi
aid
mortal
predominantli
subsaharan
africa
similar
aid
infect
measl
viru
accompani
mark
abnorm
cmi
contribut
increas
suscept
secondari
infect
account
much
morbid
mortal
diseas
measl
exacerb
presenc
hiv
coinfect
mortal
rate
north
american
case
seri
report
measl
hivposit
children
adult
far
higher
usual
case
fatal
rate
seen
unit
state
although
present
diseas
normal
mani
rash
report
giant
cell
pneumon
princip
complic
prime
caus
death
although
fatal
subacut
measl
enceph
also
describ
tcell
count
report
mani
case
report
gener
less
case
report
seri
obvious
like
bias
toward
sever
end
spectrum
diseas
howev
three
substanti
studi
investig
hivmeasl
coinfect
subsaharan
africa
studi
children
hospit
measl
kinshasa
show
similar
mortal
rate
among
hivseroposit
seroneg
children
fact
sever
ill
patient
complic
hospit
like
obviat
abil
detect
differenti
mortal
studi
initi
studi
children
measl
lusaka
reveal
significantli
higher
mortal
rate
hiv
seroposit
seroneg
second
prospect
studi
hospit
children
lusaka
distinguish
hiv
infect
hiv
seroposit
found
differ
clinic
present
complic
mortal
hivinfect
compar
uninfect
children
measl
howev
enrol
base
clinic
diagnosi
measl
would
expect
minim
abil
detect
differ
clinic
present
bia
enrol
critic
ill
children
die
soon
admiss
significantli
greater
mortal
among
hivinfect
compar
uninfect
children
among
clinic
diagnos
oppos
confirm
measl
earli
death
prior
mount
diagnost
measl
igm
titer
face
sever
immunosuppress
suspect
confound
posit
find
studi
includ
higher
proport
hiv
infect
among
children
hospit
measl
expect
matern
popul
preval
rate
greater
proport
coinfect
patient
hospit
measl
younger
age
month
longer
durat
ill
hospit
longer
hospit
coinfect
children
followup
studi
shown
coinfect
patient
higher
risk
vs
prolong
day
rash
onset
shed
measl
viru
vivo
hiv
replic
appear
suppress
acut
measl
therapi
rigor
studi
vitamin
shown
protect
sever
measl
malnourish
children
may
benefit
especi
given
margin
nutrit
statu
mani
hiv
infect
ribavirin
shown
reduc
sever
measl
normal
host
report
use
hivposit
patient
measl
pneumon
suggest
efficaci
although
rigor
data
lack
intraven
use
probabl
effect
intraven
immun
globulin
ivig
may
also
benefit
given
sever
measl
hiv
patient
prevent
key
postexposur
prophylaxi
intramuscular
immun
globulin
attenu
diseas
normal
host
recommend
acip
symptomat
hiv
patient
tcell
count
regardless
measl
serostatu
may
limit
efficaci
immunosuppress
patient
recommend
dose
mlkg
ml
maximum
given
intramuscularli
within
better
day
postexposur
prophylaxi
also
recommend
american
academi
pediatr
aap
hivinfect
children
adolesc
children
unclear
infect
statu
born
hivinfect
women
regardless
measl
immun
statu
degre
immunosuppress
preexposur
prophylaxi
monthli
ivig
advoc
hivposit
children
document
measl
vaccin
nonrespons
commun
outbreak
measl
like
econom
viabl
option
resourcepoor
area
tropic
measl
heavili
endem
vaccin
remain
princip
strategi
prevent
measl
hivinfect
peopl
normal
host
protect
efficaci
measl
vaccin
greater
vaccin
efficaci
data
hivseroposit
peopl
lack
seroconvers
data
avail
less
ideal
surrog
gener
strong
correl
level
neutral
antibodi
protect
failur
postexposur
prophylaxi
immun
serum
globulin
prevent
fatal
giant
cell
pneumonia
patient
cellular
immunodefici
note
previous
provid
compel
evid
cmi
mechan
whether
specif
nonspecif
import
even
protect
initi
infect
adult
hiv
infect
appear
wane
measl
antibodi
titer
increas
immunosuppress
unfortun
clear
data
respons
vaccin
adult
lack
antibodi
measl
children
situat
differ
hivinfect
infant
markedli
lower
rate
seroconvers
measl
vaccin
gener
lower
titer
antibodi
seroconvers
high
rate
secondari
vaccin
failur
antibodi
titer
decreas
time
increas
immunosuppress
variabl
gener
poor
respons
second
dose
vaccin
report
may
benefit
vaccin
earli
month
age
take
advantag
fact
less
hivrel
immunosuppress
earli
age
earli
vaccin
may
also
valuabl
hivposit
hivneg
infant
born
hivinfect
mother
lower
titer
matern
antimeasl
antibodi
studi
kenya
risk
acquir
measl
vaccin
month
age
standard
age
vaccin
africa
time
time
higher
confid
interv
infant
born
hivseroposit
mother
hightit
measl
vaccin
may
immunogen
hivinfect
children
discontinu
safeti
reason
children
safeti
concern
obvious
great
import
use
liveattenu
vaccin
hiv
patient
although
use
measl
vaccin
appear
quit
safe
hivinfect
children
adult
two
report
emphas
need
caution
man
hivrel
symptom
tcell
count
enumer
receiv
second
dose
measl
vaccin
prior
entri
colleg
one
year
vaccin
develop
progress
vaccineassoci
measl
pneumon
studi
effect
hiv
measl
mortal
children
hospit
measl
lusaka
zambia
also
troubl
previou
studi
suggest
prior
measl
vaccin
prevent
diseas
reduc
sever
infect
hivseroneg
boy
hospit
measl
prior
measl
vaccin
lead
significantli
lower
case
fatal
rate
although
case
fatal
rate
significantli
lower
vaccin
hivseroposit
boy
hivseroneg
girl
unvaccin
control
trend
toward
lower
case
fatal
rate
vaccine
surprisingli
howev
case
fatal
rate
higher
measlesvaccin
unvaccin
hivseroposit
girl
although
reach
statist
signific
reminisc
experi
hightit
edmonstonzagreb
ez
vaccin
use
hightit
ez
vaccin
less
month
age
associ
delay
excess
mortal
sever
studi
site
occur
exclus
femal
infant
reason
remain
unclear
notabl
zambian
studi
note
previous
highest
mortal
seen
youngest
vaccin
hivseroposit
girl
howev
region
measl
transmiss
riskbenefit
analysi
clearli
favor
measl
immun
children
regardless
hiv
statu
region
measl
transmiss
occur
immun
statu
monitor
withhold
measl
vaccin
hivinfect
children
sever
immun
compromis
wise
recommend
measl
vaccin
children
develop
countri
regardless
hiv
infect
symptom
statu
high
risk
sever
measl
gener
countri
unit
state
usphsidsa
work
group
acip
recommend
measl
vaccin
hivinfect
peopl
accord
schedul
condit
normal
host
sever
immunocompromis
addit
risk
benefit
vaccin
immun
globulin
prophylaxi
weigh
sever
immunocompromis
patient
increas
risk
due
travel
outbreak
aap
recommend
hivinfect
infant
young
adult
unit
state
includ
immun
face
sever
immunosuppress
use
measlesmumpsrubella
mmr
vaccin
month
age
second
dose
given
soon
day
first
dose
measl
transmiss
commun
vaccin
infant
young
month
old
mmr
monoval
measl
vaccin
revaccin
mmr
month
vaccin
measlessuscept
household
member
hivinfect
person
use
immun
globulin
prophylaxi
note
previous
data
avail
paramyxovirus
aid
respiratori
syncyti
viru
infect
pneumonia
may
common
bronchiol
wheez
viral
carriag
may
also
prolong
copathogen
may
occur
frequent
normal
host
ribavirin
appear
efficaci
children
adult
human
rabi
see
chapter
occur
tropic
countri
canin
rabi
still
endem
present
rabi
appear
alter
hiv
infect
hivinfect
children
adult
clearli
substandard
respons
rabi
vaccin
howev
great
stride
made
worldwid
polio
erad
see
chapter
remain
burden
poliomyel
tropic
outsid
western
hemispher
evid
hiv
infect
alter
outcom
infect
polioviru
estim
hivinfect
children
receiv
live
oral
polio
vaccin
opv
two
case
vaccineassoci
paralyt
poliomyel
hivinfect
children
report
greater
risk
vaccineassoci
diseas
face
hiv
infect
attribut
risk
thought
low
opv
remain
part
epi
children
unit
state
opv
support
acip
vaccin
recommend
polio
erad
still
transmiss
wildtyp
polio
acip
recommend
replac
opv
inactiv
polio
vaccin
vaccine
unit
state
chronic
diarrhea
common
problem
aid
patient
throughout
world
although
definit
pathogen
role
ascrib
enter
virus
small
round
structur
virus
enter
adenovirus
coronavirus
aidsrel
diarrhea
either
north
america
africa
preliminari
data
suggest
greater
diseas
sever
children
coinfect
hiv
astrovirus
associ
picobirnavirus
diarrhea
hivcoinfect
patient
noncholeraendem
area
tropic
rotaviru
probabl
princip
caus
diarrheal
death
hivuninfect
infant
rotaviru
diarrhea
appear
opportunist
pathogen
children
hiv
coinfect
larg
studi
malawi
differ
sever
rotaviru
gastroenter
found
hivinfect
uninfect
children
interestingli
rotaviru
less
frequent
detect
hivinfect
children
gastroenter
despit
equal
resolut
clinic
diseas
howev
frequenc
death
hospit
discharg
significantli
greater
coinfect
children
infect
hepat
viru
hav
see
chapter
occur
worldwid
resourcepoor
countri
especi
tropic
hav
hyperendem
exposur
viru
usual
subclin
essenti
univers
age
year
virtual
adult
immun
hivhav
coinfect
appear
associ
higher
hav
serum
viral
load
longer
durat
viremia
lower
elev
serum
alanin
aminotransferas
level
similar
diseas
cours
vaccin
hav
safe
hivinfect
patient
efficaci
wane
increas
immunosuppress
recommend
vaccin
risk
defin
neg
serolog
infect
hepat
e
viru
hev
see
chapter
local
sporad
epidem
diseas
report
mexico
north
west
africa
middl
east
south
southeast
east
asia
clinic
diseas
occur
adult
children
hev
implic
signific
interact
hiv
cosmopolitan
hepat
virus
capabl
caus
chronic
diseas
howev
sever
potenti
import
interact
hiv
describ
preval
coinfect
further
fact
virus
share
rout
transmiss
hiv
hepat
b
viru
hbv
see
chapter
cmi
respons
thought
import
resolut
acut
diseas
product
hepat
inflamm
chronic
diseas
hiv
infect
report
lead
least
threefold
increas
risk
develop
chronic
hbv
carrier
state
invers
correl
count
without
signific
chang
sever
acut
diseas
potenti
reactiv
quiescent
hbv
infect
increas
hbv
replic
decreas
inflamm
without
chronic
hepat
decreas
respons
hbv
vaccin
loss
hbv
antibodi
time
increas
liverrel
mortal
hbvinfect
individu
vaccin
hbv
reason
efficaci
hivseroposit
popul
interestingli
howev
highest
report
rate
develop
chronic
carrier
state
adult
occur
hivinfect
peopl
vaccin
time
develop
hbv
infect
hbv
appear
signific
effect
clinic
cours
hiv
infect
hepat
c
viru
hcv
infect
see
chapter
hiv
coinfect
associ
increas
risk
progress
chronic
infect
document
interact
two
virus
includ
increas
hcv
viral
load
increas
vertic
maletofemal
sexual
transmiss
hcv
probabl
due
higher
viral
load
sever
clinic
histopatholog
cours
high
percentag
indetermin
hcv
immunoblot
assay
frequent
hcv
serorevers
whether
hcv
infect
signific
effect
natur
histori
hiv
infect
respons
haart
therapi
remain
controversi
matern
hcv
infect
appear
associ
increas
risk
hiv
vertic
transmiss
treatment
hivhcv
hivhbv
infect
review
recent
data
hepat
viru
hdv
meager
hdv
replic
may
prolong
reactiv
presenc
hiv
coinfect
herpesvirus
industri
world
herp
zoster
quit
common
adult
aid
patient
tropic
histori
shingl
report
aid
patient
africa
area
africa
high
seropreval
hiv
posit
predict
valu
histori
shingl
hiv
infect
greater
elsewher
zoster
tend
develop
earli
hiv
diseas
recurr
common
chronic
genit
herp
simplex
lesion
common
throughout
world
patient
sexual
transmit
hiv
infect
cmv
infect
ubiquit
tropic
report
incid
sever
diseas
due
cmv
aid
africa
asia
although
latin
america
caribbean
lag
behind
industri
north
howev
like
greater
mortal
earlier
stage
diseas
natur
histori
diagnosi
therapi
diseas
due
coinfect
cosmopolitan
herpesvirus
discuss
elsewher
endem
central
africa
aidsrel
classic
posttranspl
kaposi
sarcoma
close
associ
human
herpesviru
see
chapter
aid
era
kaposi
sarcoma
becom
one
lead
malign
area
subsaharan
africa
epidemiolog
clinic
manifest
therapi
infect
kaposi
sarcoma
diseas
industri
world
consider
experi
earli
hiv
pandem
review
elsewher
virus
although
data
remain
somewhat
limit
cosmopolitan
influenza
viru
appear
caus
sever
diseas
hiv
coinfect
patient
prolong
symptom
higher
risk
complic
hospit
death
influenza
vaccin
safe
recommend
acip
hivinfect
patient
vaccin
shown
good
efficaci
studi
individu
mean
tcell
count
advanc
hiv
vaccin
may
gener
protect
antibodi
titer
singl
case
report
sever
acut
respiratori
syndrom
sar
coronaviru
infect
face
hiv
coinfect
within
describ
clinic
spectrum
newli
emerg
viru
associ
blood
tissu
eosinophilia
tissu
exposur
helminth
parasit
consider
diagnost
util
nonhivinfect
popul
see
chapter
data
suggest
util
may
lessen
presenc
hiv
infect
rel
absolut
eosinophilia
occur
nonparasit
reason
consider
frequenc
hivinfect
popul
rel
eosinophilia
commonli
occur
progress
hiv
diseas
least
north
american
adult
aid
patient
due
spare
absolut
blood
eosinophil
concentr
face
decreas
concentr
granulocyt
mononuclear
leukocyt
popul
effect
becom
mark
tcell
count
less
nonhelminthrel
absolut
eosinophilia
also
occur
regular
advanc
hiv
diseas
absolut
eosinophilia
north
american
hivseroposit
adult
frequent
associ
prurit
cutan
diseas
particularli
diagnos
eosinophil
pustular
follicul
atop
dermat
prurigo
nodulari
patient
count
less
remain
unclear
patient
whether
eosinophilia
primari
secondari
cutan
manifest
allerg
respons
predominantli
cutan
antigen
aid
patient
present
appear
variant
hypereosinophil
syndrom
promin
cutan
manifest
hyperigelik
syndrom
rare
caus
tissu
blood
eosinophilia
aid
patient
includ
acut
eosinophil
pneumonia
highgrad
bcell
lymphoma
advers
reaction
variou
prophylact
therapeut
agent
may
also
elicit
eosinophilia
aid
patient
caus
secondari
blood
eosinophilia
appear
quit
uncommon
north
american
aid
patient
includ
adren
insuffici
despit
high
preval
adren
autopsi
aid
patient
upshot
report
diagnost
specif
blood
eosinophilia
tissu
helminth
infect
probabl
poorer
hivinfect
hivfre
adult
patient
industri
north
conclus
somewhat
undermin
low
popul
preval
helminth
diseas
studi
cite
previous
probabl
reason
howev
avoid
extens
workup
parasit
caus
eosinophilia
adult
eosinophil
aid
patient
cutan
diseas
industri
world
howev
popul
higher
risk
helminthiasi
conclus
unwarr
absenc
prospect
studi
eosinophil
level
aid
patient
tissu
helminthiasi
eosinophilia
advanc
hiv
diseas
note
children
industri
world
data
tropic
dramat
varianc
report
industri
world
studi
patient
tuberculosi
burkina
faso
report
lower
eosinophil
level
hivseroposit
peopl
compar
seroneg
peopl
strong
correl
tcell
eosinophil
count
followup
studi
faso
report
helminth
noninfect
hiv
patient
eosinophil
count
higher
cdc
stage
b
patient
control
sever
decreas
cdc
stage
c
patient
mean
eosinophil
count
cohort
hivinfect
patient
cote
divoir
mean
tcell
count
normal
rang
hivuninfect
popul
area
world
low
preval
helminth
infect
final
case
report
england
haartrel
immun
reconstitut
schistosomeinfect
woman
southeast
africa
intrigu
patient
present
tcell
count
less
eosinophil
count
immun
reconstitut
accompani
develop
robust
eosinophila
decreas
praziquantel
treatment
taken
togeth
find
suggest
late
hiv
diseas
tropic
oppos
industri
world
associ
suppress
blood
eosinophil
level
mechan
respons
diverg
find
remain
unclear
usphsidsa
work
group
updat
guidelin
prevent
oi
hivinfect
peopl
industri
countri
data
oi
frequent
north
american
hivinfect
popul
review
factor
consid
evalu
diseas
incid
diseas
sever
term
morbid
mortal
level
immunosuppress
diseas
like
occur
feasibl
efficaci
cost
prevent
measur
impact
intervent
qualiti
life
toxic
drug
interact
potenti
drug
resist
qualiti
evid
support
recommend
prevent
oi
evalu
standpoint
prevent
exposur
prevent
first
episod
diseas
immunoor
chemoprophylaxi
primari
prophylaxi
prevent
diseas
recurr
secondari
prophylaxi
discontinu
prophylaxi
whose
tcell
count
risen
respons
haart
specif
recommend
prevent
exposur
made
sever
agent
includ
gondii
c
parvum
tuberculosi
bacteri
enter
agent
bartonella
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
cmv
human
papillomaviru
hcv
adult
adolesc
prophylaxi
prevent
first
episod
opportunist
diseas
strongli
recommend
standard
care
p
carinii
tuberculosi
face
tuberculin
skin
test
reactiv
contact
case
activ
tuberculosi
gondii
avium
complex
vzv
exposur
chickenpox
shingl
patient
without
histori
neg
serolog
vzv
varicella
zoster
immunoglobulin
vzig
primari
prophylaxi
hbv
hav
influenza
viru
pneumonia
gener
recommend
although
evid
exist
efficaci
primari
prophylaxi
c
neoforman
h
capsulatum
cmv
bacteri
infect
face
neutropenia
routin
recommend
two
agent
p
carinii
avium
primari
prophylaxi
shown
confer
surviv
benefit
secondari
prophylaxi
prevent
recurr
diseas
strongli
recommend
standard
care
p
carinii
gondii
avium
complex
cmv
c
neoforman
h
capsulatum
c
immiti
nontyphi
salmonella
speci
prophylaxi
recommend
hsv
candida
subsequ
episod
frequent
sever
children
primari
prophylaxi
strongli
recommend
standard
care
p
carinii
tuberculosi
avium
complex
vzv
vzig
gener
recommend
gondii
vzv
immun
absenc
immunosuppress
influenza
viru
recommend
unusu
circumst
invas
bacteri
infect
hypogammaglobulinemia
ivig
c
neoforman
sever
immunosuppress
h
capsulatum
sever
immunosuppress
endem
geograph
area
cmv
cmv
antibodi
posit
sever
immunosuppress
primari
prophylaxi
also
address
review
recommend
routin
immun
schedul
hivinfect
children
addit
standard
schedul
immun
hbv
hav
polio
h
influenza
type
b
diphtheria
tetanu
pertusi
alter
schedul
vaccin
pneumonia
use
heptaval
pneumococc
conjug
vaccin
begin
month
follow
pneumococc
polysaccharid
vaccin
year
influenza
yearli
dose
recommend
mmr
administr
sever
immunosuppress
children
vzv
administr
asymptomat
nonimmunosuppress
children
review
recommend
secondari
prophylaxi
similar
recommend
adult
addit
recommend
use
tmpsmx
ivig
prevent
invas
bacteri
infect
presenc
two
infect
period
recommend
like
find
broad
applic
industri
world
oi
spectrum
healthcar
prioriti
avail
prevent
option
similar
applic
much
tropic
less
clear
howev
given
differ
spectra
oi
differ
antibiot
resist
pattern
differ
sociocultur
accept
feasibl
prevent
measur
limit
avail
healthcar
resourc
includ
inabl
support
cost
mani
prevent
regimen
also
inabl
diagnos
hiv
diseas
earli
enough
prevent
measur
effect
reliabl
stage
degre
hivassoci
immunosuppress
definit
diagnos
oi
also
directli
influenc
rang
prevent
option
prioriti
also
note
compar
haart
therapi
prevent
hiv
infect
benefit
oi
prevent
reduc
hivrel
morbid
mortal
may
somewhat
modest
adequ
global
provis
haart
repres
ongo
immens
challeng
howev
wide
implement
simpl
cheap
effect
oi
prevent
strategi
provid
opportun
rapidli
wide
reduc
morbid
mortal
wide
avail
afford
effect
regimen
may
also
encourag
peopl
seek
hiv
test
kaplan
colleagu
argu
effect
research
oi
prevent
strategi
tropic
requir
integr
approach
includ
areaspecif
determin
oi
spectra
determin
environment
reservoir
opportunist
pathogen
feasibl
way
reduc
exposur
assess
immunoand
chemoprophylaxi
pathogen
improv
abil
identifi
inexpens
stage
hiv
infect
sinc
data
efficaci
oi
prevent
strategi
resourcepoor
countri
tropic
accru
first
note
previous
primari
prevent
therapi
tuberculosi
tb
isoniazid
shown
effect
hivinfect
individu
regardless
tuberculin
statu
unaid
recommend
primari
prevent
therapi
given
ppdposit
hivinfect
individu
activ
tb
set
may
feasibl
ppd
test
recommend
primari
prevent
therapi
consid
live
popul
preval
tubercul
infect
estim
healthcar
worker
household
contact
tb
patient
prison
miner
group
high
risk
acquisit
transmiss
tb
second
tmpsmxa
cheap
wide
avail
antibiot
activ
plethora
oi
includ
pcp
nontyphoid
salmonellosi
pneumococc
diseas
toxoplasmosi
malariaha
shown
reduc
morbid
mortal
hivinfect
adult
children
whounaid
recommend
tmpsmx
use
prophylaxi
adult
children
live
hivaid
africa
minimum
packag
care
adult
africa
defin
older
age
year
prophylaxi
offer
peopl
symptomat
hiv
diseas
asymptomat
count
less
total
lymphocyt
equival
pregnant
women
first
trimest
whounaidsunicef
recommend
hivexpos
children
born
hivinfect
mother
get
tmpsmx
age
week
child
identifi
hiv
infect
clinic
sign
symptom
suggest
hiv
regardless
age
tcell
count
recommend
tmpsmx
discontinu
hivexpos
children
hiv
infect
confid
exclud
mother
longer
breastfeed
hivinfect
children
antiretrovir
therapi
evid
immun
restor
occur
sever
cutan
renal
hepat
hematolog
toxic
note
mass
prophylaxi
strategi
entail
yet
quantifi
risk
princip
increas
rate
drugresist
bacteria
malaria
studi
examin
risk
perform
third
larg
random
doubleblind
placebocontrol
trial
pneumococc
polysaccharid
vaccin
hivinfect
ugandan
adult
show
protect
effect
invas
pneumococc
diseas
primari
endpoint
surprisingli
increas
rate
pneumococc
diseas
seen
vaccin
recipi
potenti
mechan
remain
unclear
surprisingli
studi
remain
controversi
fourth
among
specif
tropic
oi
control
doubleblind
trial
primari
prophylaxi
itraconazol
thailand
show
efficaci
prevent
penicilliosi
cryptococcosi
littl
data
avail
prophylaxi
tropic
oi
leishmaniasi
american
trypanosomiasi
although
util
avoid
exposur
vector
agent
diseas
clear
gener
certain
option
prevent
reduc
exposur
opportunist
pathogen
like
broadli
use
includ
avoid
unboil
water
raw
undercook
food
unpasteur
milk
prevent
enter
bacteri
protozoan
infect
well
gondii
exposur
also
avoid
contact
patient
tb
exampl
patientcar
set
avoid
exposur
opportunist
agent
dissemin
fungal
diseas
like
impract
set
clear
mani
peopl
hiv
infect
induc
hindranc
travel
hivinfect
patient
industri
world
travel
tropic
lead
increas
risk
exposur
varieti
ubiquit
well
geograph
focal
infecti
diseas
see
chapter
princip
concern
enter
respiratori
vectorborn
infect
std
deserv
special
mention
howev
despit
aid
pandem
studi
continu
document
high
frequenc
unprotect
sexual
encount
among
travel
tropic
hivinfect
travel
bear
rememb
spread
aid
pandem
along
rout
human
travel
migrat
hivinfect
travel
notifi
sexual
partner
hiv
statu
observ
safe
sex
practic
refrain
donat
fluid
tissu
inform
healthcar
provid
need
blood
precaut
avoid
share
recreat
use
needl
travel
infect
hiv
pretravel
counsel
given
strategi
minim
risk
hiv
acquisit
travel
includ
avoid
sex
new
partner
use
latex
condom
sex
rememb
condom
qualiti
vari
throughout
world
take
suppli
steril
needl
syring
routin
frequent
inject
requir
eg
insulindepend
diabet
prolong
stay
remot
area
plan
avoid
skinpierc
procedur
eg
tattoo
acupunctur
shave
barber
avoid
invas
medic
dental
procedur
possibl
cogniz
risk
motor
vehicl
travel
motor
vehicl
injuri
among
greatest
health
threat
travel
tropic
also
provid
major
risk
factor
need
emerg
blood
transfus
countri
hiv
screen
blood
suppli
routin
also
import
educ
point
hivinfect
travel
recent
review
medic
issu
hivinfect
tropic
travel
industri
world
inform
avail
wwwcdcgovtravelhiv
travhtm
care
time
pretravel
advic
plan
help
hivinfect
patient
minim
unavoid
risk
travel
tropic
issu
cover
includ
provid
adequ
suppli
current
use
medic
identifi
optim
sourc
medic
care
plan
destin
obtain
adequ
medic
insur
cover
care
discuss
potenti
legal
restrict
travel
provid
educ
avoid
food
water
vectorborn
diseas
provid
vaccin
chemoprophylaxi
antimicrobi
agent
appropri
review
medic
geographi
rout
plan
activ
identifi
special
risk
provid
adequ
medic
followup
return
travel
prior
travel
risk
hiv
infect
screen
infect
part
routin
pretravel
evalu
known
found
hiv
infect
diseas
stage
count
viral
load
level
immunosuppress
influenc
travel
medic
recommend
given
therapi
haart
complic
tropic
travel
alreadi
haart
concern
includ
problem
appropri
clinic
laboratori
monitoringfor
plan
extend
resid
place
lack
appropri
clinic
laboratori
servic
would
prudent
schedul
two
three
trip
per
year
medic
followup
countri
servic
avail
difficulti
complianc
complic
haart
regimen
disloc
chang
daili
schedul
travel
fact
approxim
countri
current
restrict
entri
infect
hiv
especi
longterm
visitor
student
worker
despit
compel
argument
util
counterproduct
natur
polici
unoffici
list
countri
requir
avail
http
travelstategovtrvelhivtestingregshtml
possess
haart
medic
may
reveal
travel
hiv
infect
potenti
solut
remov
cover
drug
label
clearli
without
risk
demand
care
record
medic
name
dosag
frequenc
physic
appear
kept
one
safe
place
travel
final
problem
untoward
drug
interact
proteas
inhibitor
initi
hiv
infect
diagnosi
andor
stage
occur
pretravel
evalu
travel
may
newli
recogn
fall
group
haart
therapi
recommend
plan
shortterm
travel
initi
haart
prior
departur
probabl
unwis
due
risk
develop
signific
side
effectsmani
tend
wors
initi
therapi
intensifi
stressin
absenc
close
contact
knowledg
provid
situat
plan
longterm
resid
tropic
departur
probabl
postpon
travel
stabli
haart
therapi
unless
close
time
followup
achiev
destin
countri
critic
variabl
ever
rapidli
chang
field
hiv
clinic
care
adequ
ongo
experi
travel
physician
without
extens
current
experi
care
hivaid
close
consult
contact
physician
possess
expertis
today
veriti
rapidli
becom
date
textbook
hiv
care
frequent
webbas
updat
also
valuabl
resourc
suffici
quantiti
current
use
medic
along
replac
prescript
essenti
patient
counsel
seek
medic
attent
promptli
ill
although
current
commun
revolut
allow
grow
number
travel
patient
stay
close
contact
hiv
travel
medicin
physician
home
via
email
prior
identif
physician
signific
hiv
experi
countri
plan
travel
prudent
obtain
medic
insur
cover
care
wise
anoth
basic
consider
especi
advanc
hivrel
diseas
buy
trip
cancel
repatri
insur
enter
pathogen
major
threat
hivinfect
travel
tropic
addit
fact
mani
tropic
travelassoci
enter
bacteri
infect
sever
presenc
hiv
coinfect
achlorhydria
occur
aid
may
markedli
lower
amount
inoculum
need
establish
infect
precaut
recommend
travel
follow
assidu
food
beverag
may
contamin
particularli
raw
unpeel
fruit
veget
raw
undercook
egg
meat
seafood
tap
water
ice
unpasteur
dairi
product
bewar
soft
chees
food
purchas
street
vendor
steam
hot
food
meat
cook
brown
throughout
water
brought
boil
minut
bottl
especi
carbon
beverag
hot
beverag
beer
wine
fruit
veget
peel
travel
gener
safe
addit
prevent
enter
diseas
follow
precaut
also
lower
risk
infect
gondii
treat
water
iodin
chlorin
may
done
prefer
conjunct
filtrat
boil
practic
filtrat
water
use
revers
osmosi
sub
micron
filter
efficaci
remov
cryptosporidia
water
tap
water
avoid
even
small
amount
use
brush
teeth
recreat
water
exposur
also
carri
risk
obvious
fecal
contamin
water
avoid
altogeth
swallow
water
swim
avoid
direct
contact
soil
sand
avoid
place
fecal
contamin
like
hand
wash
frequent
antimicrobi
prophylaxi
enter
pathogen
routin
recommend
hivuninfect
three
dose
one
mo
boost
yr
rabi
see
text
avoid
give
hdcv
given
intraderm
given
potenti
weaker
respons
japanes
enceph
three
dose
one
day
boost
base
antibodi
level
yr
routin
primari
seri
immun
diphtheriatetanu
mmr
polio
assum
absolut
rel
contraind
circumst
travel
hivinfect
travel
prophylaxi
may
consid
howev
depend
level
immunosuppress
risk
infect
durat
travel
fluoroquinolon
probabl
drug
choic
hivinfect
travel
carri
antimicrobi
without
antimotil
agent
empir
treatment
cours
case
diarrhea
develop
ciprofloxacin
mg
twice
day
day
reason
choic
altern
tmpsmx
azithromycin
use
children
pregnant
women
medic
attent
quickli
sought
empir
therapi
fail
shake
chill
hematochezia
occur
dehydr
develop
contact
arthropod
vector
reduc
care
use
insect
repel
wear
cloth
cover
arm
leg
outdoor
sleep
wellscreen
area
bed
net
avoid
outdoor
exposur
dusk
dawn
see
chapter
threat
sandfli
transmiss
viscer
leishmaniasi
see
chapter
deserv
special
mention
educ
malari
chemoprophylaxi
essenti
indic
travel
hiv
proteas
inhibitor
current
use
haart
understudi
interact
varieti
drug
use
malaria
prophylaxi
treatment
base
current
data
mefloquin
doxycyclin
chloroquin
malaron
atovaquon
proguanil
like
safe
retain
efficaci
malaria
prophylaxi
provis
empir
standbi
treatment
dose
eg
malaron
seem
prudent
recommend
immun
hivseroposit
travel
tropic
summar
tabl
prepar
travel
includ
care
review
routin
vaccin
addit
routin
special
travel
vaccin
vaccin
respons
rate
measur
antibodi
titer
tend
declin
increas
hivrel
immunosuppress
give
impetu
especi
routin
vaccin
earli
identif
need
vaccin
essenti
live
bacteri
viral
vaccin
consid
contraind
presenc
hiv
infect
includ
oral
polio
vaccin
oral
typhoid
vaccin
bcg
special
case
measl
yellow
fever
vaccin
consid
pathogencent
discuss
earlier
chapter
tabl
risk
acquisit
tuberculosi
much
higher
tropic
countri
unit
state
although
risk
becom
infect
shortterm
travel
low
note
previous
acip
usphsidsa
work
group
consid
administr
bcg
contraind
risk
dissemin
although
recommend
asymptomat
hiv
infect
area
high
preval
tb
infect
hivinfect
peopl
receiv
ppd
test
followup
test
return
tropic
travel
resid
tropic
extend
perform
posit
ppd
mm
indur
known
highrisk
exposur
hivinfect
peopl
evid
activ
tb
histori
treatment
latent
activ
tb
treat
latent
tb
whether
primari
chemoprophylaxi
recommend
travel
area
high
popul
preval
tb
unclear
endem
system
fungi
carri
consider
risk
hivinfect
travel
environment
sourc
known
risk
infect
may
reduc
somewhat
attempt
minim
exposur
measur
includ
avoid
soil
exposur
especi
raini
season
southern
china
southeast
asia
p
marneffei
avoid
exposur
disturb
soil
dust
lower
sonoran
life
zone
america
c
immiti
avoid
cave
soil
dust
exposur
area
heavi
avian
bat
excrement
h
capsulatum
often
reservoir
either
unknown
widespread
allow
avoid
primari
prophylaxi
itraconazol
mg
daili
may
merit
shortterm
prophylaxi
travel
area
high
incid
system
fungal
infect
final
may
wise
avoid
area
high
potenti
risk
chang
plan
travel
itinerari
activ
especi
peopl
advanc
hiv
diseas
regard
note
mani
tropic
infecti
diseas
special
concern
yellow
fever
fairli
focal
pattern
risk
within
endem
countri
